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Abstract
The roles of lncRNAs, particularly those regulated by the circadian transcription factors BMAL1-CLOCK, in
biological processes are poorly understood. We identified ADIRF-AS1 as a BMAL1-regulated high
amplitude circadian lncRNA, whose loss (ADIRF-AS1 KO) affected rhythmicity of cell cycle genes and
altered expression of genes associated with the extracellular matrix. Through proteomics analysis, all
components of the tumor suppressive PBAF (PBRM1/BRG1) complex as bound to ADIRF-AS1. We found
that a subset of PBAF rhythmic circadian target genes lost rhythmicity in ADIRF-AS1 KO cells. Thus, we
sought to determine how ADIRF-AS1 regulates the PBAF complex and found that differentially expressed
cell cycle and selected metabolic genes in ADIRF-AS1 KO 786O ccRCC cells could be rescued by loss of
PBRM1. Consistent with regulation of the PBAF complex, loss of ADIRF-AS1 in the 786O ccRCC cell line
did not affect in vitro growth, but in vivo tumorigenesis was absent. Tumorigenesis was partially rescued
by concurrent loss of PBRM1 in the presence of Matrigel, accounting for PBAF dependent and
independent functions of ADIRF-AS1. Further, ADIRF-AS1 is upregulated in human ccRCC and correlates
with survival, particularly in PBRM1 wild-type tumors, using TCGA data. Our findings suggest that ADIRFAS1 functions to antagonize the tumor suppressive effect of the PBAF complex and hence behaves as an
unforeseen circadian-regulated, oncogenic lncRNA.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Cell & Molecular Biology

First Advisor
Chi V. Dang

Keywords
ccRCC, Circadian Rhythm, Clock, lncRNA, Noncoding RNA, SWI/SNF

Subject Categories
Molecular Biology

This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/4714

PBAF-ASSOCIATED CIRCADIAN LNCRNA ADIRF-AS1 REGULATES RENAL CLEAR
CELL TUMORIGENESIS
Rebekah Christianna Brooks
A DISSERTATION
in
Cell and Molecular Biology
Presented to the Faculties of the University of Pennsylvania
in
Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2021
Supervisor of Dissertation
________________________
Chi Van Dang, MD-PhD
Professor, Molecular & Cellular Oncogenesis Program, The Wistar Institute Cancer Center

Graduate Group Chairperson
________________________
David M. Feldser, PhD, Associate Professor of Cancer Biology, Perelman School of Medicine
Dissertation Committee
Kathryn E. Wellen, PhD, Associate Professor of Cancer Biology, Perelman School of Medicine
Lin Zhang, MD, Harry Fields Research Professor of Obstetrics/Gynecology, Perelman School of
Medicine
Amita Sehgal, PhD, John Herr Musser Professor of Neuroscience, Perelman School of Medicine
Arjun Raj, PhD, Professor of Genetics, Perelman School of Medicine

PBAF-ASSOCIATED CIRCADIAN LNCRNA ADIRF-AS1 REGULATES RENAL CLEAR CELL
TUMORIGENESIS
COPYRIGHT
2021
Rebekah Christianna Brooks

This work is licensed under the
Creative Commons AttributionNonCommercial-ShareAlike 4.0
License
To view a copy of this license, visit

https://creativecommons.org/licenses/by-nc-sa/4.0/us/

ACKNOWLEDGMENT
This work was supported by NIH/NCI grants F31-CA232551-03 (RCB),
R01CA051497 (CVD), and R01CA57341 (CVD), Ludwig Institute for Cancer
Research, and the Patel Family Scholar Award (RCB).

I thank Dr. Chi Dang for his unwavering optimism that carried me through the
many years of my PhD. I thank him for his brilliant insight, patience,
approachability, unfaltering support, enthusiasm, and setting the example for
integrity, honesty, and generosity. I could not have imagined a better mentor, and
I am extremely thankful and fortunate to have learned from him.

I thank the Next Generation Sequencing Core at the University of Pennsylvania
who made the libraries and sequenced the reads for one of the sequencing
experiments presented in this body of work. Dr. Lin Zhang aligned the raw data
to the genome, annotated the reads, and processed the data to reported
fragments per kilobase of transcript per million mapped reads. This experiment
was collected by Dr. Zandra Walton and has been published in Walton et al1.

Subsequent sequencing experiments were sequenced by The Wistar Institute
genomics core. I thank Dr. Shashi Bala and Dr. Sonali Majumdar who prepared
the libraries and sequenced the reads as well as answered my questions and
who were always willing to troubleshoot with me. I also thank Dr. Andrew
Kossenkov, Scientific Director of The Wistar Bioinformatics Facility for
iii

sequencing analysis and always being available to discuss bioinformatic
approaches.

Proteomics experiments were performed at The Wistar Institute. We would like to
thank Dr. David Speicher and Dr. Hsin-Yao Tang and the Wistar Proteomics and
Metabolomics Core Facility for the proteome analyses funded by P30 CA010815
awarded to The Wistar Institute Cancer Center.

I thank Dr. Lin Zhang for his support as a collaborator, as described above, and
mentor as a member of my thesis committee. I also thank Dr. Amita Sehgal and
Dr. Arjun Raj for their guidance and encouragement.

I thank Dr. Kathryn Wellen for her unwavering support and for being an
exemplary scientist and mentor.

I thank Dr. Celeste Simon for the many helpful suggestions and her commitment
to teaching that provided me with formative instruction as a rotation student in
her lab. I also thank Dr. Brian Keith for his thoughtful support and feedback
through the grant proposal process and for the illuminating conversations that
helped to shape the narrative of this project.

I thank Dr. William Kaelin for sharing key cell lines necessary for completion of
this project.

iv

I thank the Cell and Molecular Biology department and Cancer Biology graduate
group for their support. I thank Dr. Dan Kessler, Dr. Craig Bassing, and Dr.
Sandra Ryeom for their guidance and support. I also thank Dr. Donita Brady for
her mentorship and support during my first graduate rotation.

I thank the many Dang lab members who I treasure as colleagues and friends. I
especially thank Dr. Zandra Walton for her example and setting the highest bar
as a graduate student in the Dang lab. I thank her for our many scientific
conversations that helped drive this project from day 1, and for encouraging me
to apply my undergraduate bioinformatic skills towards analyzing the RNA
sequencing collected in the Dang lab. I also especially thank Dr. Brian Altman for
our many scientific and career conversations that have shaped my PhD
education. I thank him for being an amazing example of a scientist and for his
generous instruction when I first joined the Dang lab. I especially thank Dr.
Zachary Stine for his excellent guidance and formative instruction while I was a
rotation student in the lab as well as his feedback and encouragement
throughout the grant writing process. I especially thank Dr. Adam Wolpaw for
being a remarkable mentor to me, being a rich source of happiness on my worst
science days and bringing perspective to understand and value my best days in
lab. I also thank him for his valuable scientific conversation that helped focus this
project. I thank Dr. Xue Zang for her encouragement and valuable scientific
conversation. I thank Patricia Brafford for her helpful support and our many
v

wonderful conversations. I thank other Dang lab members who each made it a
joy to show up each day: Dr. Annie Hsieh, Dr. Jennifer Matsui Heitz, Yaoyu
Gong, May Dong, Jessi Dessau, and Dr. Vivian Li. I thank Judith Monzy for her
diligence as a lab technician and her many hours of work; I also thank her for
being a joy to work with. I thank Dr. Hongguang Shao and Bailey Aaron for their
help injecting tumor xenografts described in this project. I also thank Bailey
Aaron for her encouragement and many laughs in the mouse house. I thank
Shaun Egolf for his diligence as a rotation student in optimizing the CRISPRi
protocol.

I thank my mom, dad, and siblings, Joshua, Stephen, Paul, Phillips, and Rachael,
for instilling in me the value of integrity and perseverance.

I thank my husband, John Woodley for being my support that enabled this project
(i.e., bringing me food during over-night circadian time courses) and our many
adventures together. I thank Kayla Degenshein for her encouragement and
valuable figure suggestions. Lastly, I thank my friends for putting up with my
themed parties and the many D&D adventures that have brought me perspective
and many laughs.

vi

ABSTRACT
PBAF-ASSOCIATED CIRCADIAN LNCRNA ADIRF-AS1 REGULATES
RENAL CLEAR CELL TUMORIGENESIS
Rebekah Christianna Brooks
Chi Van Dang

The roles of lncRNAs, particularly those regulated by the circadian transcription factors
BMAL1-CLOCK, in biological processes are poorly understood. We identified ADIRFAS1 as a BMAL1-regulated high amplitude circadian lncRNA, whose loss (ADIRF-AS1
KO) affected rhythmicity of cell cycle genes and altered expression of genes associated
with the extracellular matrix. Through proteomics analysis, all components of the tumor
suppressive PBAF (PBRM1/BRG1) complex as bound to ADIRF-AS1. We found that a
subset of PBAF rhythmic circadian target genes lost rhythmicity in ADIRF-AS1 KO cells.
Thus, we sought to determine how ADIRF-AS1 regulates the PBAF complex and found
that differentially expressed cell cycle and selected metabolic genes in ADIRF-AS1 KO
786O ccRCC cells could be rescued by loss of PBRM1. Consistent with regulation of the
PBAF complex, loss of ADIRF-AS1 in the 786O ccRCC cell line did not affect in vitro
growth, but in vivo tumorigenesis was absent. Tumorigenesis was partially rescued by
concurrent loss of PBRM1 in the presence of Matrigel, accounting for PBAF dependent
and independent functions of ADIRF-AS1. Further, ADIRF-AS1 is upregulated in human
ccRCC and correlates with survival, particularly in PBRM1 wild-type tumors, using TCGA
data. Our findings suggest that ADIRF-AS1 functions to antagonize the tumor
suppressive effect of the PBAF complex and hence behaves as an unforeseen
circadian-regulated, oncogenic lncRNA.
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CHAPTER 1: Introduction

Circadian Rhythm
Biological systems, similar to well-engineered mechanical systems, gain
robustness from the incorporation of feedback loops and redundancy. In a 1956
study of isoleucine biosynthesis in E. coli, Umbarger surmised that “in the
internally regulated machine, as in the living organism, processes are controlled
by one or more feedback loops that prevent any one phase of the process from
being carried to a catastrophic extreme.”2 While some feedback loops are
triggered and resolved in direct response to stimuli, such as end-product
inhibition3, regulating the timing of cooperative feedback loops setting an
acceptable amplitude for sustained oscillation to achieve biological rhythms, such
as circadian rhythms4,5. Circadian rhythms are conserved across evolution and
are perhaps one of the most exquisite links between biology and the
environment, connecting the natural day-night cycle to life on earth. Through
careful genetics investigation, the molecular components comprising the
circadian molecular clock were discovered in the 1970s and 80s, earning Jeffrey
C. Hall, Michael Rosbash, and Michael W. Young the Nobel Prize in 20176.
Circadian rhythms are driven by the master clock, located in the
hypothalamus, and peripheral clocks, found in nearly every tissue of the body,
leading to 24-hour periodicity in metabolic patterns7. The circadian clocks
synchronize cellular activities with the organismal sleep-wake, fasting-feeding
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cycle to optimize metabolic flux (Box 1). The molecular clocks are composed of
interlocking transcription-translation negative feedback loops. BMAL1
heterodimerizes with CLOCK (or NPAS2) to upregulate genes that subsequently
act to downregulate BMAL1 activity (Per, Cry) and RNA (Reverb, Rors). Thus,
24-hour oscillatory activity of the BMAL1:CLOCK heterodimer leads to the
circadian transcription of hundreds of clock output genes7-9. Molecular clocks
allow for synchrony with the environment and can segregate opposing biological
processes, providing a robust control over homeostasis and cell state. In a
mouse tissue-selective manner, roughly 10-40% of the genome exhibits periodic
expression patterns, including coding and noncoding transcripts, and genes
associated with metabolism, tumorigenesis, and oncogenes, such as MYC, are
also directly regulated by the molecular clock10,11. Further, in a study of 64
tissues from baboons, over 80% of transcripts were found to oscillate in at least 1
tissue12 (Box 2).
Box 1: Hierarchically organized circadian clocks.
Circadian rhythm is a conserved temporal regulation of gene expression
which synchronizes cellular activity with nutrient availability and the 24-hour
light-dark cycle. This temporal regulation results in clear, sinusoidal
patterns of body temperature, metabolism, and other core biological
processes of the whole organism. In humans, the suprachiasmatic nucleus
(SCN) in the hypothalamus, known as the Central Clock, and external
environmental cues coordinate circadian gene expression by synchronizing
peripheral cellular clocks, found in most tissue.
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These peripheral clocks can be sustained in clock competent cell lines, and
in order to study these clocks in a population, synchronization is necessary.
This can be accomplished by serum shock or dexamethasone13.

Deviation from a standard the sleep-wake cycle is correlated to many
disease states. There are correlations between specific disease incidents and the
time of day. For example, the influence of circadian rhythms on vasculature has
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been long established14, and this is associated with myocardial infarction and
stroke occurring more often during the early morning hours due a rapid rise in
blood pressure15,16. Some disease states are associated with phase dissociation,
such as sleep disorders17. In addition, chronic disruption in sleep patterns, such
as night shift, has been correlated with increased cancer incidence leading to
night shift work being declared a “probable” carcinogen in 2007 and further
supported by subsequent studies on the incidence of breast cancer in night shift
nurses18,19. While there are clear connections between the molecular clock and
regulation of the cell cycle, discussed further in the next section, treating
circadian rhythms as a therapeutic target has only recently gained attention given
the complexity of molecular circadian rhythm10.

Box 2: The molecular clock.
Peripheral clocks are composed of interlocking transcription-translation
feedback loops. The master circadian transcription factor BMAL1 stimulates
the transcription of its own negative regulators via E-box binding motifs. PER
and CRY negatively regulate BMAL1 protein, while REVERBα and β
negatively regulate the transcription of BMAL1 via ROR response elements
(RORE). This results in oscillating BMAL1 leading to the downstream
oscillation of many hundreds of clock-controlled genes (CCGs) which include
both protein coding and noncoding transcripts. Figure adapted from Walton et
al10.
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The Molecular Clock and the Cell Cycle
In 1917, Droogleever Fortuyn-van Leijden described an association
between time of day and mitotic events in growing tissues collected from cats.
The circadian molecular clock and the cell cycle function independently but these
cellular oscillators can be coupled. This coupling is the result, in part, of core
clock transcription factors that regulate cell cycle components. For example,
REV-ERBα suppresses p21 transcription20, BMAL1 suppresses MYC21 or
induces Wee122, and subsequently, MYC induces G1 cyclins such as cyclin E123.
In addition, the p53 tumor suppressor gene has been shown to be regulated by
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the clock. The degradation of p53 is inhibited by PER2 that can bind p53 directly
to slow MDM2 mediated p53 degradation leading to disrupted target gene
expression, including p2124,25. There are multiple computational models that aid
in understanding the coupling of the molecular clock and the cell cycle26,27. In
addition, the DNA damage response is also regulated by the molecular clock.
Deletion of Per2 in mice lead to an increased incidence of radiation-induced
tumorigenesis, demonstrating the link between the circadian clock and response
to biological hazards21. In addition, PER1, which is often downregulated in
human cancers, can directly bind to cell cycle checkpoint proteins ATM and
Chk228. Further understanding of the links between the core clock machinery and
the cell cycle will reveal additional mechanisms of how clock perturbation can
contribute to tumorigenesis.
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Box 3: The molecular clock and the cell cycle.

The circadian molecular clock intersects with the cell cycle at multiple
hubs. Figure adapted from Walton et al10.

Noncoding RNA
The vast majority of the mammalian transcriptome does not code for
protein production, a striking realization upon the development of sequencing
technologies29. While historically regarded as “junk,”30 non-protein coding RNAs
have since been found to harbor incredibly diverse functions both through unique
regulation as well as functional RNAs31, some even encoding small functional
polypeptides32. Among noncoding RNA subtypes (others include microRNAs,
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small nucleolar RNAs, and small interfering RNAs), lncRNAs are defined as
transcripts over 200 nucleotides and are categorized as intergenic, intronic,
divergent, enhancer, or antisense RNAs33. While antisense transcription was
primarily considered to regulate the sense strand transcription of protein coding
genes34, these lncRNA can act as functional molecules by interacting with DNA,
RNA, and proteins31. They can be post-transcriptionally regulated to dictate
cellular localization and half-life, leading to a broad spectrum of context
dependent function35-37. Thus, lncRNAs can act as critical components of cell
biology and physiology.

Circadian Regulated lncRNAs
Comprising most of the mammalian transcriptome, it has been a
herculean effort to parse out the functions of individual noncoding RNAs or even
identify the subset with important biologic roles. Noncoding transcripts with high
circadian amplitudes are surmised to have important cellular functions38.
LncRNAs can regulate the surrounding chromatin in cis, affecting transcriptional
regulation of neighboring genes, and are capable of trans functions where they
affect long-range changes, often through proteins interactions39-41. Like circadian
protein coding transcript expression, circadian lncRNA expression is tissue
specific in mice11,38. Some have been shown to regulate enhancer regions,
mediating circadian chromatin architecture, thus lncRNA with short half-lives can
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function through their transcription to mediate specific chromatin interactions42.
Regulation of RNA stability plays a role in circadian expression patterns as only
~22% of cycling transcripts in mouse liver were dependent on direct transcription,
but rather post-transcriptional regulation43. Noncoding RNA stability is impacted
by a variety of factors including cellular localization, GC content, and secondary
structure35. Thus, the genomic landscape, regulation, and RNA localization and
stability of circadian lncRNA are important factors to consider towards
determining RNA function.
Many circadian lnRNA remain uncharacterized, but there are several
examples of recently discovered functional lncRNA that regulate important
cellular functions and, in some cases, in turn regulate the molecular clock.
Recently, the circadian antisense lncRNA Per2AS, encoded on the antisense
strand of the core clock gene Per2, has been shown to regulate clock amplitude
in a transcription dependent mechanism by inhibiting Per2 transcription and
possibly in a transcription independent mechanism through the regulation of
Bmal144. In addition, NRON, the noncoding repressor of NFAT (nuclear factor of
activated T cells), acts as a scaffold for a complex that is essential for PER/CRY
nucleocytoplasmic translocation45. Lnc-UC, a direct BMAL1:CLOCK target gene,
blocks Cbx1 epigenetic silencing of Reverb-α, an interaction that links the
circadian clock and colitis pathophysiology46. However, the functions of the
majority of circadian lncRNA largely remain unknown. In our study reported here,
we discovered that the high amplitude circadian ADIRF-AS1 lncRNA can function
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in trans through interacting with a Switch/sucrose nonfermentable (SWI/SNF)
complex.

The SWI/SNF Complex in Cancer
The SWI/SNF complex is a chromatin modifying complex whose components are
mutated in over 20% of all human cancers47 (Box 4a). The mSWI/SNF complex
is composed of protein machinery, combinatorially assembled into three major
subcomplexes: canonical BRG1/BRM-associated factor (BAF), polybromoassociated BAF (PBAF), and non-canonical BAF (ncBAF) complexes48. The
PBAF complex is a multicomponent, ATP dependent SWI/SNF chromatin
modifying complex that can affect the expression of thousands of genes. The
PBAF complex specifically contains PBRM1, ARlD2, PHF10, and BRD7 and can
include the ATPase BRM or BRG149. In a global study of RNA binding proteins,
both shared (Brg1, Smarce1, Smarcb1) and PBAF specific (Brd7, Pbrm1)
proteins were found to bind RNAs50. RNA interactions with SWI/SNF proteins can
add tissue specific regulation to the chromatin modifying activity of SWI/SNF41,5155

, such as the interaction of SWINGN with SMARCB1 which promotes the

transcription of GAS6 and other oncogenic factors56. In addition, SMARCA4
binds to many primary transcripts in prostate cancer, and these interactions are
not well understood57,58. Further characterizing interactions between RNAs and
the mSWI/SNF complexes is critical to understanding the basic biology of
mSWI/SNF in cancer52,55,59. The function of RNA binding to the PBAF complex
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has not been investigated in clear cell renal carcinoma (ccRCC)49,60, the most
common form of kidney cancer, where PBRM1 is mutated in over 40% of cases
(Box 4b).
PBRM1 inactivating mutations are most common in ccRCC and
cholangiocarcinoma61-67. A frequent genomic alteration in ccRCC is the biallelic
inactivation of the E3 ligase VHL, which destabilizes hypoxia inducible factors
(HIF1 and HIF2)68 that activate genes involved in glycolysis, glutamine uptake,
lipid metabolism, and angiogenesis69. The loss of VHL is not sufficient to induce
ccRCC; subsequent mutations cooperate with VHL loss to promote tumor
initiation, and the most commonly co-mutated gene is PBRM1. PBAF complex
chromatin remodeling antagonizes HIF-directed transcription of metabolic
genes66 and VEGFA. A pan-cancer study of metastatic ccRCC found that
PBRM1 loss of function mutations were associated with the induction of
angiogenesis70, and downregulating PBRM1 in ccRCC cell lines promotes tumor
progression60,66. Thus, the oncogenic loss of PBRM1 in ccRCC allows for
augmented HIF activation and transcription of metabolic target genes and
increased angiogenesis71. PBRM1 mutations are associated with decreased
gene expression of DNA damage repair genes, and PBAF has been shown to
play a critical role through multiple mechanisms70,72-74 (Box 4c). Due to the
importance of PBRM1 in DNA damage repair, Chabanon et al. discovered that
loss of PBRM1 or ARID2 lead to synthetic lethality with PARP inhibitors75. Taken
together, the PBAF complex plays an important role in the regulation of the
11

hypoxia response as well as DNA damage repair and has tumor suppressive
function in ccRCC.
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Box 4: The PBAF complex in ccRCC.

We hypothesized that high amplitude, cycling lncRNAs have important
cellular function as they are uniquely regulated by the molecular clock. To test
this hypothesis, we discovered and characterized the circadian lncRNA ADIRFAS1, determined interactors, and evaluated the impact of ADIRF-AS1 loss of
function on osteosarcoma U2OS cell proliferation in vitro and ccRCC
tumorigenesis in vivo. Our study uncovers that ADIRF-AS1 binds the PBAF
chromatin modifying complex and drives ccRCC tumorigenesis, revealing an
unforeseen link between a clock-regulated lncRNA and tumorigenesis in ccRCC.
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Project aims and summary
While noncoding RNAs (ncRNAs) as a group are much more abundant
than protein coding RNAs, the functions of individual ncRNAs remain largely
unknown. While clock-controlled proteins have important roles in cell cycle
regulation and metabolism, little is known about the function of clock-controlled
ncRNAs. I identified that the most significantly clock-controlled ncRNA in U2OS
cells is a long noncoding RNA (lncRNA) of unknown function, ADIRF-AS1.
Unbiased proteomics analysis revealed an association between ADIRF-AS1 and
the PBAF chromatin modifying complex (Box 5).
Clear cell renal carcinoma (ccRCC) is a lethal tumor of the kidney with
frequent loss of von Hippel-Lindau (VHL) protein, which mediates the
degradation of the hypoxia inducible factors. The loss of VHL is insufficient for
tumorigenesis; about 40% of ccRCC patients also gain a mutation in the tumor
suppressor PBRM1. PBRM1 is a component of the chromatin modifying
switch/sucrose nonfermentable (SWI/SNF) Polybromo- and BRG1-associated
factors-containing (PBAF) complex. The PBAF complex can hinder or promote
chromatin accessibility of many genes.
Thus, we hypothesized that ADIRF-AS1 could modulate PBAF activity to
regulate gene expression of PBAF target genes and subsequently tumorigenesis.
We aimed to: 1. Characterize the circadian regulation of ADIRF-AS1 and 2.
Determine the PBAF dependent role of ADIRF-AS1 in ccRCC tumorigenesis ().
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Here, we discovered that an important tumor suppressive complex, PBAF, is
post-translationally regulated by a circadian controlled lncRNA, ADIRF-AS1, and
this research will inform future studies toward understanding potential
vulnerabilities of ccRCC.
Box 5: Proposed model.
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Chapter 2: Results

Identification and characterization of a functional circadian lncRNA
From data collected as part of our study demonstrating that low pH can
disrupt the circadian clock and transcriptome1, we sought to identify high
amplitude circadian noncoding RNAs in our RNA-seq data generated from U2OS
cells1. However, the evaluation of a transcript’s rhythmicity is not trivial, and there
are multiple factors, such as the baseline and amplitude (Fig 1a), that must be
considered and several algorithms to determine these factors.
The expression pattern of circadian transcripts can be irregular and lead to
both false positive and negative “hits.” For example, we used the MetaCycle
package to run the ARSER, JTK, and Metacycle algorithms to find circadian
lncRNA. We compared three highly expressed lncRNA that have previously been
shown to be circadian in certain contexts, NEAT1, PVT1, and MALAT1. We
found that ARSER called NEAT1 and MALAT1 significantly oscillatory while
MetaCycle and JTK called PVT1 and MALAT1 (Fig 1b,c). To determine which
algorithm is best, we took into account the sampling: we are using a gene
expression dataset where samples were collected every four hours for 52-hours.
The ARSER algorithm detrends data before detecting rhythmicity within a defined
period range (20-28 hours) using both autoregressive spectral analysis and
harmonic regression76, and this algorithm performs optimally on a two day time16

course with 4-hour resolution, as is used in our study76,77. We also used
Metacycle, an additional algorithm that incorporates strategies from ARSER,
JTK_CYCLE, and Lomb-Scargle (LS)78.
In addition to determining significance, the cutoff for expression level and
amplitude should also be considered. First, we performed MetaCycle analysis on
noncoding transcripts only that had a mean FPKM over 2 (n=1177). We then took
all lncRNA that had either a Metacycle or ARSER p-value of less than 0.05. Next,
we evaluated the rhythmicity by the relative amplitude, baseline expression, and
benjamini-hochberg q (BH.Q). While there are 203 lncRNA that meet the initial
expression level and p-value cutoffs, the majority of these lncRNA are lowly
expressed and have a low relative amplitude (rAMP), which is determined by the
ratio of the amplitude and baseline (Fig 1d). From this initial analysis however,
several lncRNA stood out as having both highly significant by ARSER and
MetaCycle (by p-value and BH.Q) and having a high rAMP. Among those with a
high rAMP (greater than 0.5), ADIRF-AS1 has the highest baseline expression.
ADIRF-AS1 was an uncharacterized lncRNA and exhibited a striking diurnal
expression pattern, thus igniting our interest to determine its function.
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Figure 1: Identification of circadian controlled noncoding RNA. A. Illustration
of MetaCycle output values including the baseline (yellow) expression, amplitude,
and the relative amplitude. B. ARSER, JTK, and MetaCycle output for NEAT1,
PVT1, and MALAT1. C. NEAT1, PVT1, and MALAT1 RNA-seq FPKM and D.
18

lncRNA with a MetaCycle or ARSER p-value below 0.05 shown with the bubble
size indicating the BH.Q value and the color indicating the relative amplitude,
generated from U2OS cells cultured at pH 7.4 (Walton et al.1).

ADIRF-AS1 is regulated by BMAL1
Based on the above discussion, we sought to identify a subset high amplitude
circadian noncoding RNAs in our RNA-seq data generated from U2OS cells1 (Fig
2a, Table 1). Among the group of oscillating noncoding RNAs, the lncRNA
ADIRF-AS1 (ENSG00000272734) exhibited high amplitude expression. We
verified high amplitude, diurnal expression of ADIRF-AS1 in U2OS cells by RTqPCR (Fig 2b).

Figure 2: Oscillatory ADIRF-AS1 expression. A. Circadian noncoding RNAs
(meta2d pvalue < .01, FDR < .2, meta2d_AMP > 2), U2OS. B. RNA was
collected every 4 hours for 52 hours from synchronized U2OS cells, and
expression of ADIRF-AS1 was quantified by RT-qPCR.
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Table 1: High amplitude, oscillating lncRNA.
Ensembl
ENSG00000272734
ENSG00000228065
ENSG00000233016
ENSG00000224078
ENSG00000273096
ENSG00000269609
ENSG00000261295
ENSG00000278642
ENSG00000214174
ENSG00000257621

Gene
ADIRF-AS1
LINC01515
SNHG7
SNHG14
RP3-508I15.20
RPARP-AS1
RP11-524D16__A.3
RP11-159D12.11
AMZ2P1
PSMA3-AS1

GeneType
lncRNA
lncRNA
lncRNA
lncRNA
lncRNA
lncRNA
lncRNA
lncRNA
pseudogene
lncRNA

Table 1: High amplitude, oscillating lncRNA. List of the high amplitude
(meta2d pvalue < 0.01, FDR < 0.2, meta2d_AMP > 2) cycling lncRNA.

Analysis of publicly available ChIP-seq data revealed that BMAL1 binds
directly to the promoter of ADIRF-AS1 in U2OS cells79 (Fig 3a). To determine if
ADIRF-AS1 diurnal expression is dependent on BMAL1, we collected protein and
RNA every 4 hours for 52 hours from control and BMAL1 KO U2OS cells, which
lack a functional circadian clock80. We verified loss of BMAL1 expression and
decreased level of REVERBα, a clock-controlled protein, by immunoblot analysis
(Fig 3b). As anticipated, 24-hour periodic ADIRF-AS1 expression and amplitude
were lost in BMAL1 KO cells (Fig 3c). To further explore the regulation of ADIRFAS1, we constructed an ADIRF-AS1-promoter luciferase reporter, which contains
a BMAL1 target E-box binding site. The robust diurnal oscillation of the ADIRF20

AS1 luciferase reporter was lost in U2OS CRISPR-cas9 mediated BMAL1 KO
cells compared to control cells (Fig 3d), further documenting ADIRF-AS1 as a
BMAL1 target gene.

Figure 3: ADIRF-AS1 is a BMAL1 target gene. A. BMAL1 Chip-seq
(GSM1081127) from U2OS cells, UCSC genome browser of ADIRF-AS1. B.
Immunoblot analysis of BMAL1, REVERBα, and αTUB in U2OS sgSCR and
sgBMAL1 cells, lysates collected every 4 hours after dexamethasone
synchronization, and C. RT-qPCR analysis of ADIRF-AS1. D. Continuous
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luminescence monitoring of synchronized ADIRF-AS1::dLUC (pGL4.15)
expressing U2OS sgSCR and sgBmal1 cells. (BR = 3, RE of >3)

As our previous study found that low pH leads to clock suppression via
dampened translation of BMAL11, we next asked whether ADIRF-AS1 was
similarly impacted by low pH. At low pH, ADIRF-AS1 continued to significantly
oscillate according to the Metacycle algorithm (Fig 4a). Thus, we asked the
question whether ADIRF-AS1 is regulated by BMAL1 at pH 6.3 and acidification
due to hypoxia. We collected RNA every 4 hours for 52 hours at normoxia,
hypoxia, and hypoxia buffered against media acidification (hypoxia high buffer).
We found that ADIRF-AS1 expression decreased in hypoxia and its expression
was rescued in the hypoxia high buffer condition (Fig 4b). This suggests that the
expression of ADIRF-AS1 is susceptible to the changes in BMAL1 and the
molecular clock at low pH. To determine if residual ADIRF-AS1 diurnal
expression is dependent on BMAL1 at low pH, we collected protein and RNA
every 4 hours for 52 hours from control and BMAL1 KO U2OS cells cultured at
pH 6.3, as previously published1. We found that oscillatory ADIRF-AS1
expression was lost in BMAL1 KO cells at low pH (Fig 4c). Thus, continued
expression of ADIRF-AS1 at low pH is likely due to low levels of BMAL1
expression, diminishing over prolonged exposure to low pH as detailed in Walton
et al1.

22

Figure 4: ADIRF-AS1 regulation at low pH. A. Diagram depicting clock
sensitivity to pH (Walton et al). B. lncRNA with a MetaCycle or ARSER p-value
below 0.05 shown with the bubble size indicating the BH.Q value and the color
indicating the relative amplitude, generated from U2OS cells cultured at pH 6.3
(Walton et al.). C. ADIRF-AS1 expression generated from U2OS cells cultured at
normoxia, hypoxia, or hypoxia in media buffered against acidification.

Loss of ADIRF-AS1 does not disrupt BMAL1 oscillation
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As circadian ADIRF-AS1 is regulated by BMAL1, we asked whether
ADIRF-AS1 may in turn, regulate the core clock or a subset of the circadian
transcriptome. We knocked out ADIRF-AS1 using flanking CRISPR sgRNAs and
identified single-cell clones with paired primers spanning the ADIRF-AS1
genomic locus followed by RT-qPCR RNA expression analysis (Fig 5a-c). To
test for changes in the core clock, we used a Bmal1 luciferase reporter
(Bmal1::dLuc), and we found no change in the diurnal oscillation of the reporter
signal in dexamethasone-synchronized ADIRF-AS1 KO U2OS cells compared to
the polyclonal sgSCR control cells (Fig 5d).

Figure 5: U2OS ADIRF-AS1 KO cells maintain oscillatory BMAL1 luciferase
signal. A. ADIRF-AS1 flanking primers; UCSC genome browser. B. PCR
amplification of ~300kbp gDNA region only after the CRISPR-cas9 sgRNAs have
successfully removed the ADIRF-AS1 gDNA region (RE of n>3). C. ADIRF-AS1
24

expression by RT-qPCR in U2OS sgSCR or clonal sgADIRF-AS1 cells. (one-way
ANOVA; RE > 3) D. Bmal1 luciferase reporter (Bmal1::dLuc) in U2OS sgSCR
and sgADIRF-AS1 (#1 and #2) (RE of >3).

Loss of ADIRF-AS1 disrupts the expression of clock output cell cycle genes
We next sought to determine whether loss of ADIRF-AS1 disrupts the
circadian transcriptome. We collected protein and RNA every four hours for 52
hours after dexamethasone synchronization of control and ADIRF-AS1 KO U2OS
cells. After confirming absent ADIRF-AS1 expression in the knockout by RTqPCR (Fig 6a) and continued circadian BMAL1 protein levels by immunoblot (Fig
6b), we carried out Quant-seq 3’ mRNA-sequencing and analysis of control cells
compared to two U2OS ADIRF-AS1 KO clonal cell lines.

Figure 6: U2OS ADIRF-AS1 KO time course. A. U2OS sgSCR and sgADIRFAS1 clones 1 and 2 were synchronized, and RNA was collected every 4 hours for
52 hours. Expression of ADIRF-AS1 over the timecourse was measured by RT25

qPCR (normalized to B2M). B. Circadian rhythm and oscillating cell cycle gene
expression (sgSCR ARSER pvalue < .05) heatmaps ranked by the sgSCR
phase.

We identified 1,306 significantly oscillating genes (ARSER p-value < .05)
in control cells. All but 31 of these genes lost significant oscillation (ARSER pvalue < .05) in both ADIRF-AS1 KO clones (Fig 7a, b). The ARSER algorithm
detrends data before detecting rhythmicity within a defined period range (20-28
hours) using both autoregressive spectral analysis and harmonic regression76,
and the performance of this algorithm on a two day time-course with 4-hour
resolution, as is used in our study, has been validated76,77. While components of
the core clock retained significant diurnal expression in ADIRF-AS1 KO,
transcripts that no longer maintain circadian expression after ADIRF-AS1 loss
revealed that these were predominantly cell cycle transcripts (Fig 7c). Of a cell
cycle geneset (BioSystems Reactome geneset, n=624), 60 genes were
significantly oscillating in control cells. Diurnal expression of these genes was
lost in both ADIRF-AS1 KO cell lines, and the rAMP of these genes was
significantly decreased. Known cell cycle genes that are regulated by the
circadian clock including cyclins (ie CCNE2) and DNA damage regulators,
including ATM, were among this group of repressed genes.
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Figure 7: ADIRF-AS1 is regulated by the molecular clock and involved in
sustaining diurnal expression of cell cycle genes. A. U2OS sgSCR and
sgADIRF-AS1 clones 1 and 2 were synchronized, and RNA was collected every
4 hours for 52 hours. Expression of ADIRF-AS1 over the timecourse was
measured by RT-qPCR (normalized to B2M). B. Circadian rhythm and oscillating
cell cycle gene expression (sgSCR ARSER pvalue < .05) heatmaps ranked by
27

the sgSCR phase. C. Gene ontology pathways for significantly oscillating genes
in sgSCR control cells (ARSER pvalue < .01) that do not exhibit significant
diurnal expression in sgADIRF-AS1 clones (ARSER pvalue > .01). D. genes
within BioSystemsREACTOME_Cell Cycle (60 oscillating out of 624 genes in
geneset) that significantly oscillate (Metacycle, ARSER) (ANOVA) and their E.
relative amplitudes (ANOVA). *p≤0.05, **p≤0.01, ns = p>0.05. RE =
representative experiment. BR = biological replicates.

As loss of ADIRF-AS1 lead to decreased cyclic expression of cell cycle
genes, we hypothesized that ADIRF-AS1 may play a role in proliferation. We
found that among differentially expressed genes, CDKN1A that codes for the
tumor suppressive p21 was significantly upregulated in ADIRF-AS1 KO cells
compared to controls (Fig 8a). We also found elevated p21 expression in ADIRFAS1 KO cells compared to control (Fig 8b). Unsynchronized ADIRF-AS1 KO
U2OS cells had no shift or accumulation of cells within a cell cycle phase (Fig
8c), but loss of ADIRF-AS1 blunted cell proliferation compared to control (Fig
8d). In addition, ADIRF-AS1 KO U2OS cells were outcompeted by control cells in
a proliferation competition assay where control or ADIRF-AS1 KO cells were
labeled with GFP, and vice versa (Fig 8e).
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Figure 8: Differential gene expression after loss of ADIRF-AS1 in U2OS
cells. A. Normalized counts for CDKN1A across the 52-hour time course (twoway ANOVA). B. Immunoblot analysis of p21 and αTUB in U2OS sgSCR and
sgADIRF-AS1 c1. C. Cell cycle analysis (Mean of 3 BR; one-way ANOVA). D.
Cell titer glo cell growth assay of U2OS sgSCR and sgADIRF-AS1 cell lines.
(two-way ANOVA). E. Competition assay using unlabeled and GFP labeled
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U2OS control and ADIRF-AS1 KO cells (Mean of 3 BR, RE of 2) RE =
representative experiment. BR = biological replicates.

We also sought to determine differentially expressed genes after loss of
ADIRF-AS1. Pathway analysis of differentially expressed genes in ADIRF-AS1
KO cells were predominantly associated with the extracellular matrix (ECM) (Fig
9a,b). Thus, loss of ADIRF-AS1 lead to decreased cyclic expression of cell cycle
genes, through dampened amplitude, and a decrease in proliferation of U2OS
cells, and ADIRF-AS1 KO cells exhibited differentially expressed ECM genes.
Given these widespread changes in gene expression, we sought to determine
the mechanism by which ADIRF-AS1 functions.

Figure 9: Differential gene expression after loss of ADIRF-AS1 in U2OS
cells. A. Heatmap of differentially suppressed (n=184; p-adj < 0.05 and
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log2foldchange < 0) and induced (n=351; p-adj < 0.05 and log2foldchange > 0)
genes in sgADIRF-AS1 cells compared to sgSCR. (DESeq2) B. Gene ontology
for DEGs (p-adj < 0.05) in ADIRF-AS1 KO cells.

ADIRF-AS1 binds the PBAF complex
LncRNAS can function in cis to regulate neighboring genes or in trans to
regulate distant genes or cellular components42,81,82. ADIRF-AS1 is encoded on
the antisense strand of the adipocyte regulatory factor gene (ADIRF), a
transcription factor regulator of lipid metabolism during early adipocyte
differentiation83. ADIRF was not detected in U2OS cells via immunoblot analysis
as compared to A431 positive control cells and PC3 negative control cells where
the genomic locus is deleted (Fig 10a). Thus, the effect of ADIRF-AS1 in U2OS
is unlikely in cis; however, it is possible that in other cell lines or tissues that
clock-controlled expression of ADIRF-AS1 facilitates circadian expression of
ADIRF as ADIRF is diurnally expressed in fat visceral, among other tissues, in
humans84 and baboons12. However, due to large transcriptomic changes in cell
cycle genes after ADIRF-AS1 loss and decreased proliferation in CRISPR KO
cells in the absence of detectable ADIRF expression, we hypothesized that
ADIRF-AS1 functions in trans through interactions with protein binding partners.
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Figure 10: ADIRF-AS1 binds the PBAF complex. A. Immunoblot analysis of
ADIRF and α-TUB in A431, PC3, U2OS (sgEV, sgADIRF-AS1 c1/2/3, and 786O
dCas9 sgCtrl, sgADIRF-AS1 #4, #7). B. lncRNA pulldown against U2OS WCL,
protein silver stain (Lanes: 1. Input, 2. Beads Only, 3. Negative control antisense
of LOC105371288, 4. ADIRF-AS1, 5. Antisense control of ADIRF-AS1). C. Gene
ontology of the top 100 proteins enriched by biotinylated ADIRF-AS1 pull down
compared to antisense or random RNA controls. (Mean of 3 BR).
We performed a biotinylated lncRNA pulldown assay using U2OS whole
cell lysate (WCL) followed by proteomics analysis by mass spectrometry. For
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controls, we used the antisense RNA of ADIRF-AS1 as well as the antisense of
an additional non-coding RNA (LOC105371288)85. After washing steps, bound
proteins were verified by silver stain prior to proteomics analysis (Fig 10b). We
performed pathway analysis on the top 100 proteomic hits enriched in the
ADIRF-AS1 pulldown compared to controls. We found that SWI/SNF complex
components were significantly overrepresented in the ADIRF-AS1 pulldown
compared to controls (Fig 10c), specifically, components of the PBAF chromatin
modifying complex. All PBAF complex proteins, including the bromodomain
containing protein BRG1-associated factor 180 (BAF180 or PBRM1) and the
ATPase BRG1, were enriched in the ADIRF-AS1 pulldown compared to controls
(Fig 11a,b). Proteins specific to the BAF or ncBAF complexes were not enriched
in the ADIRF-AS1 pulldown (data not shown). Consistent with its association with
the PBAF complex, we found that ADIRF-AS1 localizes mostly to the nucleus in
U2OS cells (Fig 11c). This finding is consistent with its nuclear localization in
other cell lines according to GENCODE RNA-seq data (data not shown,
https://lncatlas.crg.eu/) and the nuclear localization of the PBAF complex66.
To determine which PBAF component putatively interacts with ADIRFAS1, we evaluated the interaction of each PBAF component with ADIRF-AS1 in
silico. Using catRapid (http://s.tartaglialab.com/page/catrapid_group), we found
that ADIRF-AS1 potential binding to SMARCA4 and PBRM1 had the highest
interaction propensity, a measure of interaction strength with respect to a training
set, compared to other PBAF components or WDR5 negative control, a protein
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subunit of other chromatin modifying complexes and not enriched by ADIRF-AS1
pulldown86,87 (Fig 11d). In addition, the interaction propensity of ADIRF-AS1
binding to PBRM1 was significantly higher compared to that of PBRM1 with
control RNAs (GAPDH and MALAT) (Fig 11e). Consistent with this in silico
analysis, our proteomics analysis revealed that PBRM1 had the highest median
iBAQ enrichment score by ADIRF-AS1 and not the antisense control RNA (Fig
11f). Thus, we immunoprecipitated endogenous PBRM1, and in support of our
proteomics analysis, we found enrichment of ADIRF-AS1 compared to other
highly expressed transcripts and the IgG control (Fig 11g).
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Figure 11: ADIRF-AS1 binds the PBAF complex, and PBAF target genes are
disrupted in ADIRF-AS1 KO U2OS cells. A. Heatmap of proteomics iBAQ
enrichment score of PBAF complex components. B. The PBAF complex pseudocolored by the iBAQ enrichment score. (Not enriched: white, high enrichment:
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dark blue) C. Cell fractionation of U2OS cells. Nuclear and cytoplasmic RNA
expression was analyzed by RT-qPCR analysis and normalized to total. (RE of 2)
D. catRapid (Fragments) interaction propensity for WDR5 negative control and
PBAF components (PHF10, BRD7, SMARCB1, SMARCD2, SMARCC2, ARID2,
SMARCA4, PBRM1) for predictive binding with ADIRF-AS1. E. catRapid
(Fragments) interaction propensity for PBRM1 predictive binding with ADIRFAS1 and GAPDH and MALAT negative controls. F. Proteomics enrichment score
(iBAQ) of PBAF components pulldown by ADIRF-AS1 (BR = 3, median with 95%
CI). BR = biological replicates. D. RNA immunoprecipitation (RIP) against
PBRM1 from U2OS nuclear lysate. (RE of 3)

As the PBAF complex has known tumor suppressive activity in certain
cancers, particularly ccRCC88, and loss of ADIRF-AS1 lead to decreased
proliferation in U2OS cells, we hypothesized ADIRF-AS1 negatively regulates the
PBAF complex. First, we determined that the mRNA expression of PBAF
components was not affected by loss of ADIRF-AS1 (data not shown), and we
did not find any significant change to the protein expression of PBRM1 or BRG1
as measured by immunoblot (Fig 12a). Next, we analyzed publicly available
ChIP-seq data for PBAF binding (PBRM1/SMARCC1/H3K27ac ChIP-seq;
GSE139216)89. Of 1,591 circadian transcripts (ARSER pvalue < 0.05) in control
U2OS cells, 135 genes had a ChIP-seq peak corresponding to
PBRM1/SMARCC1/H3K27ac chromatin binding89. We found that these 135
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PBAF controlled genes had decreased amplitude and 132 of these no longer
significantly oscillate in sgADIRF-AS1 cells (Fig b,c), likely due to decreased
amplitude (Fig 12d). Given the well-established role of PBAF as a tumor
suppressor in ccRCC, we sought to determine whether ADIRF-AS1 might act as
an oncogene in ccRCC through antagonizing PBAF.

Figure 12: ADIRF-AS1 KO cells exhibit disrupted diurnal expression of
PBAF target genes. A. Immunoblot of PBRM1 and BRG1 across CT 24-44 in
control and ADIRF-AS1 KO U2OS cells. B. Heatmap of PBAF target genes that
significantly oscillate in control U2OS cells and C. their ARSER p-value and D.
rAMP.
ADIRF-AS1 is regulated by the clock and binds PBAF in 786O ccRCC cells
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First, we sought to determine whether ADIRF-AS1 functions similarly in a
ccRCC cell line as it does in U2OS. We used the ccRCC cell line 786O, which
expresses WT PBRM1 and ADIRF-AS1 (Fig 13a, b). We tested whether ADIRFAS1 is regulated by BMAL1 in 786O cells as in U2OS. Using siRNAs to silence
BMAL1, we found that BMAL1 knockdown decreased both NR1D1, a Bmal1
target gene, and ADIRF-AS1 (Fig 13c). We also found that synchronized 786O
cells expressing the ADIRF-AS1 luciferase reporter lost robust circadian
luciferase signal after silencing BMAL1 (Fig 13d). Further, we analyzed ccRCC
TCGA data and found that the expression of ADIRF-AS1 was negatively
correlated with CLOCK and ARNTL2 and conversely positively correlated with
negative regulators of BMAL1::CLOCK, REVERBα and REVERBβ (NR1d1 and
NR1d2) as well as PER1 and CRY2 (Fig 13e). This analysis suggests that
ADIRF-AS1 is regulated by the clock in some human ccRCC cases. These data
demonstrate that in 786O cells, there is an intact clock and diurnal expression of
ADIRF-AS1 depends on BMAL1. Next, similar to in U2OS cells, we verified that
ADIRF-AS1 localizes to the nucleus (Fig 13f) and that ADIRF-AS1 interacts with
the PBAF complex by native RNA immunoprecipitation using an antibody against
PBRM1 (Fig 13g) and biotinylated RNA pull-down assays in 786O cells (Fig
13h). Thus, similar to U2OS cells, ADIRF-AS1 is regulated by the circadian
molecular clock and binds the PBAF complex component, PBRM1.
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Figure 13: ADIRF-AS1 is regulated by the molecular clock and binds the
PBAF complex in 786O ccRCC cells. A. Immunoblot analysis of PBRM1 and
BRG1 and B. RT-qPCR of ADIRF-AS1 in ccRCC cell lines with WT (black: 786O,
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769P, UMRC2, A498) and mutant PBRM1 (grey: CAKI2, RCC4, RCC10). C.
siRNA against BMAL1 (10nM) in 786O and A498 cells expressing a pGL4.15
ADIRF-AS1 promoter luciferase reporter. Expression of BMAL1, NR1D1, and
ADIRF-AS1 were analyzed by RT-qPCR. (RE of 2, unpaired t-test) D.
Continuous luminescence monitoring of synchronized 786O and A498
expressing ADIRF-AS1::dLUC cells treated with siNC or siBMAL1. (RE of 2, 4
BR) E. TCGA KIRC expression analysis of ADIRF-AS1 and molecular clock
genes (n=533). F. Cell fractionation of 786O cells. Nuclear and cytoplasmic RNA
expression was analyzed by RT-qPCR analysis and normalized to total. (RE of 2)
G. PBRM1 RIP followed by RT-qPCR using nuclear lysate from the ccRCC cell
line 786O. (RE of >3) H. lncRNA pulldown assay using nuclear lysate from the
ccRCC cell line 786O. (RE of 2) RE = representative experiment. BR = biological
replicates.

ADIRF-AS1 expression in ccRCC is correlated with survival
We found that ADIRF-AS1 directly interacts with and antagonizes the
function of the PBAF complex in ccRCC, potentially serving as a mechanism to
inhibit the PBAF complex. Thus, we hypothesized that increased expression of
ADIRF-AS1 would only lead to decreased survival in patients with PBRM1 WT
tumors, but not in those with PBRM1 mutant tumors. High expression of PBRM1
(Fig 14a) correlates with better clinical outcomes and improved survival in
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ccRCC patients60,66,88, and high expression of ADIRF-AS1 correlates with
decreased survival (Fig 14b). Unlike ADIRF-AS1, ADIRF expression is not
correlated with survival in ccRCC TCGA data (Fig 15c). Consistent with our
hypothesis, the inverse correlation between ADIRF-AS1 expression and survival
was only evident in patients with WT PBRM167,90 (Fig 14d, e). These data,
combined with the expression changes of PBAF target genes in U2OS ADIRFAS1 knockout cells, support our hypothesis that ADIRF-AS1 functions as an RNA
inhibitory regulator of the PBAF complex that can be upregulated to dampen the
tumor suppressive function of PBAF in ccRCC.
We compared ADIRF-AS1 expression in ccRCC to that in normal tissue
and found that ADIRF-AS1 is significantly elevated in tumor compared to normal
tissue (Fig 14f). TCGA data demonstrates that ADIRF-AS1 expression is higher
in bulk tumor compared to normal tissue, but this analysis is unable to
differentiate tumor cells from other cell types that may be present. In order to
validate our TCGA analysis, we analyzed publicly available single cell RNA-seq
data from human ccRCC patients91. Consistent with our TCGA data analysis,
ADIRF-AS1 is elevated in putative tumor compared to normal tissue (Fig 14g).
Intriguingly, ADIRF-AS1 expression is higher in a subset of cells characterized by
increased angiogenesis91 (Fig 14h). This is notable, since PBRM1 loss has been
noted to have limited effects on ccRCC cells in vitro, but results in accelerated
tumorigenesis in vivo, thought to be due to reversal of PBAF-mediated
dampening of hypoxia response and angiogenesis pathways. Thus, informed by
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our analysis of TCGA and single cell RNA-seq data, we hypothesized that that
loss of ADIRF-AS1 would lead to increased PBAF activity and dampen ccRCC
tumorigenesis due to disrupted angiogenesis.
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Figure 14: ADIRF-AS1 expression in human ccRCC. A. Kaplan Meier curves
for high versus low ADIRF-AS1 expression in PBRM1 WT (low=136, high=137)
samples (left) and B. PBRM1 mutant samples (low=87, high=88) (right). C.
Kaplan Meier analysis of PBRM1 expression from TCGA KIRC data (median
cutoff, high: n=263; low: n=262), p=0.034. Data displayed through R2
(https://r2.amc.nl/). D. Kaplan Meier analysis of ADIRF-AS1 expression from
TCGA KIRC data (median cutoff, high: n=267; low: n=266), p=0.022. E. Kaplan
Meier analysis of ADIRF expression from TCGA KIRC data (median cutoff, high:
n=267; low: n=266), p=0.074. F. TCGA expression (FPKM) of ADIRF-AS1 in
normal and tumor tissue. (unpaired, t-test; pvalue =0.0006) G. UMAP cell
embeddings of lymphoid, myeloid, putative tumor and normal tissue, and H.
expanded UMAP cell embeddings with ADIRF-AS1 expression from
https://singlecell.broadinstitute.org/single_cell/study/SCP1288.

ADIRF-AS1 expression modulates PBAF target genes in ccRCC
As the PBAF complex has been shown to dampen the hypoxia response
pathway66 and single cell RNA-seq analysis revealed that ADIRF-AS1 expression
was found in an angiogenic tumor cell population91, we hypothesized that loss of
ADIRF-AS1 expression could lead to decreased expression of angiogenic
pathways known to be critical for tumorigenesis in ccRCC92. First, we used
CRISPRi to stably silence ADIRF-AS1 in 786O cells and determined ADIRF-AS1
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expression by RT-qPCR (Fig 15a). Similar to our previous results, CRISPRi
mediated knockdown of ADIRF-AS1 did not affect the protein expression of the
PBAF complex or proliferation in vitro (Fig 15b, c). Next, we collected RNA
samples for QuantSeq 3’ mRNA-sequencing followed by differential expression
and GSEA analysis. We found differentially expressed genes were predominantly
associated with extracellular matrix organization, similar to differentially
expressed genes in U2OS (Fig 15d, e). Similar to previous analysis of PBAF
target genes92, we found that hallmark hypoxia and angiogenesis genesets were
dampened in ADIRF-AS1 KD cells (Fig 15f), consistent with our hypothesis that
ADIRF-AS1 antagonizes the PBAF complex.
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Figure 15: Loss of ADIRF-AS1 in 786O cells disrupts hypoxia response
gene expression. A. RT-qPCR of ADIRF-AS1 in CRISPRi mediated knockdown
of ADIRF-AS1. (RE of > 3) B. Immunoblot analysis of PBAF components
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(PBRM1, PHF10, BRG1, SMARCC1, SMARCB1) and αTUB in 786O CRISPRi
mediated knockdown of ADIRF-AS1. (n=3) C. Growth curve of 786O CRISPRi
mediated knockdown of ADIRF-AS1. D. Heatmap of differentially expressed
genes defined by DESeq2 analysis (p-value < 0.05). ) E. Gene ontology of
differentially expressed genes (p-value < 0.05) in CRISPRi mediated ADIRF-AS1
KD 786O compared to control cells. F. GSEA analysis of hallmark hypoxia (left)
and angiogenesis (right) pathways.

Next, we evaluated a subset of seven previously described PBAF
suppressed genes66, and found that nearly all were significantly decreased in
CRISPRi ADIRF-AS1 KD cells (Fig 16a) and in CRISPR-cas9 with flanking
sgRNAs mediated ADIRF-AS1 KO cells (Fig 16b, c) that also maintain PBRM1
expression with some clonal variation (Fig 16d). Consistent with PBAF regulating
the expression of these genes via reorganizing chromatin, and not by modifying
HIF expression, we found that HIF-2α expression is unchanged in ADIRF-AS1
KO 786O cells, and 786O cells do not express HIF-1α69,93 (Fig 16d). Together,
these data strongly suggest that ADIRF-AS1 regulates the PBAF complex and
antagonizes its effect on angiogenesis and hypoxia genes.
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Figure 16: Loss of ADIRF-AS1 impacts PBAF target genes. A. Normalized
counts of PBAF suppressed genes in 786O cells with CRISPRi mediated
knockdown of ADIRF-AS1 (two-way ANOVA, Dunnett’s multiple comparisons
test, BR = 3). B. RT-qPCR analysis of ADIRF-AS1 in 786O CRISPR-cas9 sgEV
and sgADIRF-AS1 cells. (RE of >3) C. RT-qPCR of PBAF suppressed genes in
clonal, CRISPR-cas9 mediated ADIRF-AS1 KO compared to control (sgEV)
cells. (two-way ANOVA, Dunnett’s multiple comparisons test) D. Immunoblot
analysis of PBRM1, HIF-2α, and αTUB in 786O cells with PX458 CRISPR KO of
control (sgEV) or ADIRF-AS1 (clones 23, 36, 41). (RE, n=3).
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ADIRF-AS1 affects PBRM1 activity
We hypothesized that ADIRF-AS1 could antagonize the chromatin binding
of the PBAF complex or inhibit its activity. First, we determined that there was no
shift in sedimentation of PBRM1 after glycerol gradient centrifugation in CRISPRi
ADIRF-AS1 KD cells compared to control (Fig 17a). This suggests that loss of
ADIRF-AS1 did not affect the PBAF complex gross composition as assessed by
centrifugation sedimentation48. Next, we carried out ChIP-qPCR at select PBAF
target genes (CCND1, VEGFA) which revealed that while the occupancy of
PBRM1 was unchanged, H3K27ac (enriched at active chromatin) was
significantly decreased at CCND1 and VEGFA and not in the RPL30 control (Fig
17b, c). ChIP-seq of H3K27ac further demonstrated decreased H3K27ac at the
promoter region of CCND1 and VEGFA in ADIRF-AS1 KO cells (Fig 17d). These
observations are consistent with the model that ADIRF-AS1 binds to and
modulates the activity of the PBAF complex at specific targets genes but does
not change occupancy or complex composition.
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Figure 17: Loss of ADIRF-AS1 impacts PBAF activity. A. Glycerol gradient
centrifugation of CRISPRi mediated knockdown of ADIRF-AS1 (sgRNA #4) and
control (sgNC) nuclear lysates, fractions 5-20 (5ml gradient; 200ul fractions). (RE
of BR=2). B. ChIP using antibodies targeting IgG, PBRM1 or H3K27ac followed
by qPCR analysis of RPL30 ribosomal RNA and PBAF suppressed genes
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(Ccnd1, Vegfa) (two-way ANOVA) C. Genome browser view of CCND1 and D.
VEGFA from ChIP-seq using antibodies targeting IgG or H3K27ac.

Loss of ADIRF-AS1 inhibits tumorigenesis
It has been well documented that PBRM1 loss in 786O cells leads to no
change in cell proliferation in vitro and an increase in tumor burden in vivo66.
Similarly, silencing ADIRF-AS1 in 786O cells had no impact on PBAF protein
expression or in vitro proliferation. We sought to test our hypothesis that loss of
ADIRF-AS1 expression diminishes tumorigenesis in 786O cells, in which PBRM1
behaves as a tumor suppressor66. As 786O cells form tumor xenografts, maintain
an intact PBAF complex66, and exhibit high ADIRF-AS1 expression, we used this
cell line to study ADIRF-AS1’s role in tumorigenesis.
To study the loss of function effect of ADIRF-AS1 expression on
tumorigenesis, we also used multiple loss of function (LOF) models. First, we
used CRISPR-cas9 to stably target and disrupt the transcription start site of
ADIRF-AS1. We used sgRNAs specific to the BMAL1 E-box binding site in the
promoter region of ADIRF-AS1. We verified knockdown of ADIRF-AS1 via RTqPCR analysis (Fig 18a). We found that the 786-O ADIRF-AS1 KD had severely
blunted tumor volume and weight compared to the control (Fig 18b-d). This LOF
model suffers from several shortcoming, namely: (1) each clone is derived using
a single sgRNA making a cut in the TSS of the ADIRF-AS1 locus and we did not
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validate whether these cuts are present on both alleles, (2) these are only two
clonal cell lines and there is likely clonal genetic drift resulting in differences of
tumorigenesis, (3) due to the small amount of tumor tissue recovered, we were
unable to carry out RT-qPCR analysis to verify that ADIRF-AS1 expression
remained low in the knockdown cell lines. Given the caveats of these ADIRF-AS1
transcription site mutant clones, we used other methods that addressed these
concerns.
To further determine if ADIRF-AS1 is required for tumorigenesis of 786O
ccRCC cells, we used CRISPRi to knockdown ADIRF-AS1 followed by
subcutaneous xenografts. After 42 days, there was no significant difference
between the sgROSA control and sgADIRF-AS1 tumors (Fig 18e, f). However,
we anticipated that ADIRF-AS1 KD cells may be outcompeted by cells with
higher levels of ADIRF-AS1. As anticipated, we found that the sgADIRF-AS1 KD
expressed similar levels of ADIRF-AS1 as the sgROSA control tumors (Fig 18g),
suggesting that ADIRF-AS1 is required for tumorigenesis of the ccRCC 786O cell
line. Thus, we surmised that cells expressing low ADIRF-AS1 had a growth
defect in vivo. The sgRNA #4 population exhibited a delay in tumor growth post
injection and compared to sgRNA #7 had decreased ADIRF-AS1. In addition to
similar levels of ADIRF-AS1 in dissected tumors after 42 days, these CRISPRi
modified cells exhibited much slower tumor growth compared to the PX458 sgEV
control and parental 786O cells (Fig 18b, data not shown). Thus, constitutive
expression of the dCas9, regardless of sgRNA target, may have a growth defect
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in the 786O cell line. It is possible that this is due to an immune response given
that athymic nude mice still have an NK and B cell population and CRISPR-cas9
components can cause an immunogenic response in some circumstances94,95.
Because of these potential confounding factors, we sought to eliminate the
ADIRF-AS1 sequence using CRISPR-cas9.
In order to stably knockout ADIRF-AS1 in 786O cells for tumor xenografts,
we used CRISPR-cas9 and two sets of flanking sgRNAs to make clonal 786O
ADIRF-AS1 KO cells, as described for U2OS cells. This addresses several
caveats of the other models. Unlike the TSS targeting and CRISPRi method,
using flanking CRISPR sgRNAs completely knocks out the lncRNA, removing the
possibility of ADIRF-AS1 expressing cells to grow out. In addition, we carried out
a transient transfection followed by clonal selection. We validated loss of
expression using RT-qPCR (Fig 16b). After expanding the clonal cell line, we
found that the GFP signal was lost (data not shown), thus the cas9 is no longer
expressed in these cells, unlike the CRISPRi system. The main caveat to this
method is the potential for clonal effects, but we addressed this by using three
separate clones using two different sgRNA sets. The other possible issue is the
loss of ADIRF, which is encoded on the sense strand. Even though we were
unable to detect ADIRF expression in 786O cells using both qPCR and western
blot analysis, it remains possible that ADIRF is upregulated in vivo and is
important for tumorigenesis. In all three cell lines, loss of ADIRF-AS1 expression
resulted in a profound lack of tumorigenesis (Fig 18h) that resulted in no
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retrievable tumor tissue. This striking phenotype demonstrates that ADIRF-AS1
is necessary for tumorigenesis in 786O ccRCC cells.
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Figure 18: ADIRF-AS1 is required for tumorigenesis of 786O ccRCC cells.
A. RT-qPCR analysis of ADIRF-AS1 in control and ADIRF-AS1 KD (clonal lines,
c2.10 and c3.21) via targeting the transcription start site (TSS). B. Tumor volume
(two-way ANOVA; *p≤0.05, **p≤0.01, ns = p>0.05), C. size and D. weight of
ADIRF-AS1 KD (t-test) compared to control cells. E. Tumor volume, F. tumor
weight, and G. RT-qPCR analysis of ADIRF-AS1 expression of RNA collected
from tumor tissue of polyclonal, CRISPRi mediated knockdown of ADIRF-AS1 in
786O cells using sgRNAs #4 and #7 compared to control (sgROSA). (unpaired ttest) H. Tumor volume of three clonal ADIRF-AS1 KO cell lines (flanking CRISPR
sgRNAs) compared to a control (sgEV, “empty vector”) clonal cell line (two-way
ANOVA; *p≤0.05, **p≤0.01, ns = p>0.05).

ADIRF-AS1 KO cells were not fully rescued by ADIRF-AS1 WT 786O cells in
vivo
We found that loss of ADIRF-AS1 inhibited tumorigenesis of 786O cells in
athymic nude mouse xenografts. To test whether the lack of tumorigenesis is due
to a cell intrinsic or extrinsic effect, we co-injected a 1:1 mixture of control and
ADIRF-AS1 KO 786O cells into athymic nude mice (Fig 19a). After 39 days,
tumors were collected, weighed, and gDNA was isolated. Consistent with our
previous analysis, ADIRF-AS1 KO cells alone did not form tumors, and we were
unable to recover tumor tissue for gDNA isolation. However, we carried out PCR
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analysis with control and mixed tumors using a primer specific to control cells. All
tumors contained PCR amplicons associated with control cells, and tumors with a
mix of control and ADIRF-AS1 KO cells exhibited the PCR amplicon specific to
ADIRF-AS1 KO cells indicating their presence in these tumors’ cells (Fig 19b-d).
This suggests that ADIRF-AS1 KO cell tumorigenesis was, at least in part,
recovered when co-injected with control cells.
Tumors formed after co-injection of 50% control and 50% ADIRF-AS1 KO
cells had decreased tumor volume and weight compared an equal number of
100% control cells, indicating that the control cells were unable to fully rescue the
KO cells in vivo (Fig 19b,c). It is possible that the ADIRF-AS1 KO gDNA from
dead cells remained in the tumor or ADIRF-AS1 KO cells survived but exhibited
blunted proliferation in vivo. In order to verify recovery of tumorigenesis of
ADIRF-AS1 KO cells by extrinsic factors, we co-injected GFP labeled ADIRFAS1 KO cells (GFP+) with parental 786O cells (Fig 19a). In vitro, the GFP signal
was stable at around 50% of the population, as expected with a 1:1 mixture and
no in vitro growth difference between control and ADIRF-AS1 KO cells (Fig 19e).
Tumors with ADIRF-AS1 KO cells mixed with parental cells exhibited reduced
tumor volume and weight (Fig 19f,g). After 40 days, we collected tumors and
made single cell suspensions and flow sorted cells to determine the percent
GFP+ cells within the population of human specific cells (CD147). Consistent
with our previous analysis, GFP+ ADIRF-AS1 KO cells mixed with GFP- ADIRFAS1 KO cells did not form tumors (Fig 19f). Control GFP+ cells mixed with
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parental resulted in a median of 87% GFP+ population, suggesting that this clone
outcompetes the parental cell line. ADIRF-AS1 KO GFP+ cells mixed with
parental cells represented only 5-10% of the total tumor cell population,
suggesting that in vivo ADIRF-AS1 KO cells could persist in vivo in the presence
of the parental cell line (Fig 19h). These observations suggest that parental cells
provide an in vivo milieu for the persistence of ADIRF-AS1 KO cells that have cell
intrinsic defects for tumorigenesis.
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Figure 19: ADIRF-AS1 KO cells are outcompeted by control cells in vivo. A.
Schematic of mixing experiment. B. Tumor weight (n=5, ANOVA) and C. tumor
volume of xenografts using 786O control (sgEV), ADIRF-AS1 KO (clones 23, 36,
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41) and co-injection with ADIRF-AS1 KO (clone 36) and sgEV cells in athymic
nude mice (2 million cells/injection) (n=5, ANOVA). D. PCR amplification of gDNA
(100ng) from tumor tissue using primers specific to WT (Primer 1) or ADIRF-AS1
KO (Primer 2). E. Percent population of GFP+ cells within the total cell population
of mixed cells. F. Tumor volume and G. weight of mixed cell population (n=5,
ANOVA). H. Percent GFP positive cells within the CD147 (human specific)
population (n=2, ANOVA). RE = representative experiment. BR = biological
replicates.

Given that ADIRF-AS1 KO cells are outcompeted by parental cells, and
that these mixed tumors (ADIRF-AS1 KO mixed with parental) had significantly
decreased tumor weights, less than 50% of control, compared to the control
mixed (sgEV with parental), it appears that ADIRF-AS1 KO cells inhibited the
tumorigenesis of parental cells. Nonetheless, the presence of putative
extracellular factors provided by parental cells was sufficient to maintain the
presence ADIRF-AS1 KO cells within the tumor. These observations suggest that
ADIRF-AS1 provides cell intrinsic and extrinsic mechanisms for tumorigenesis. In
this regard, we sought to determine if these mechanisms are PBRM1 dependent.

ADIRF-AS1 expression modulates PBAF activity at target genes in 786O cells
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We first determined if loss of ADIRF-AS1 modulates PBAF target gene
expression in a PBRM1 dependent manner. Consistent with PBAF regulating the
expression of these genes via reorganizing chromatin, and not by modifying HIF
expression, we found that HIF-2α expression is unchanged in ADIRF-AS1 KO
786O cells and 786O cells do not express HIF-1α69,93 (Fig 16d). We suspected
that loss of ADIRF-AS1 might lead to high PBAF activity and subsequent
epigenetic changes (Fig 20a), as ADIRF-AS1 KO 786O cells exhibited significant
decrease in H3K27ac of PBAF target genes (Ccnd1, Vegfa). While the precise
mechanism of how the PBAF complex promotes inhibition of hypoxia response
genes remains unclear, mutations in PBAF complex subunits are associated with
increased dependence on EZH2, a catalytic subunit of the polycomb repressive
complex 2 (PRC2)96,97, and there is a clear relationship between the BAF
complex opposition of PRC recruitment and gene repression98. However,
pharmacologic inhibition of the PRC2 complex neither through EZH2
(EPZ011989, GSK2879552) nor targeting a histone demethylase, KDM1a,
(Iadademstat) was sufficient to rescue expression of VEGFA and ANGPTL4 in
ADIRF-AS1 KO cells compared to control cells (Fig 20b). In control cells,
EPZ011989, GSK2879552, and Iadademstat treatment led to a significant
decrease in VEGFA expression (Fig 20b). In Arabidopsis thaliana, the SWI/SNF
complex binds to proteins associated with lncRNA mediated gene silencing
through DNA methylation99. We therefore suspected that it is possible for high
PBAF activity to be sufficient to result in durable epigenetic suppression of
VEGFA via DNA methylation (Fig 20a). We found that cells treated with
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decitabine, a hypomethylating agent, fully rescued VEGFA expression in ADIRFAS1 KO cells compared to controls and induced high levels of ANGPTL4 in both
control and ADIRF-AS1 KO cells compared to the vehicle control cells (Fig 20b).
However, when decitabine pre-treated cells (5 days followed by 20 day washout;
5 million cells, no Matrigel) were injected into athymic nude mice, no tumors were
observed (data not shown), suggesting that transient decitabine treatment was
not sufficient to rescue tumorigenicity.
The expression level of PBAF target genes were only rescued with the
hypomethylating agent and not the other epigenetic modifiers. Thus, we
wondered whether PBRM1-dependent gene expression is affected by the order
of PBRM1 and ADIRF-AS1 knockout. If loss of ADIRF-AS1 lead to DNA
methylation events that were unable to be reversed by loss of PBRM1, then gene
expression changes could only be rescued when PBRM1 was knocked out prior
to ADIRF-AS1. As such, we determined the effect of PBRM1 loss before and
after ADIRF-AS1. Using the flanking CRISPR sgRNA mediated ADIRF-AS1 KO
cells, we further knocked down PBRM1 using the lentiCRISPRv2 system
previously used by Gao et al66. We found that this failed to rescue ANGPTL4 or
VEGFA expression in the DKO cells (Fig 20c-e). It should be noted, however,
that PBRM1 knockdown was incomplete, so there could be some influence of
residual PBAF activity. Next, we sought to knockout PBRM1 prior to ADIRF-AS1
to further explore the hypothesis that order of knockout matters for the PBRM1
dependent expression changes due to ADIRF-AS1 loss.
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Figure 20: Gene expression changes due to ADIRF-AS1 loss are rescued by
decitabine. A. Model for using epigenetic inhibitors. B. RT-qPCR of PBAF
suppressed genes (VEGFA, ANGPTL4) after treatment of inhibitors: EPZ011989
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(3uM, 10 days), GSK2879552 (1.7uM, 10 days), Iadademstat (2uM, 10 days),
decitabine (5aza, 0.5uM, 5 days) (RE of BR>3, ANOVA). C. Immunoblot analysis
of PBRM1 with ADIRF-AS1 KO cells treated with the lentiCRISPRv2 system to
subsequently knockout PBRM1 or control. D. RT-qPCR analysis of ADIRF-AS1
and E. ANGPTL4 and VEGFA in DKO cells. (two-way ANOVA, Dunnett’s multiple
comparisons test; *p≤0.05, **p≤0.01, ns = p>0.05) RE = representative
experiment. BR = biological replicates.

PBRM1 is necessary for ADIRF-AS1 to modulate PBAF target genes in 786O
cells
Next, we sought to determine if loss of PBRM1 prior to ADIRF-AS1
knockout could prevent the effect of ADIRF-AS1 loss on the expression of PBAF
target genes. As we observed decreased expression of PBAF target genes,
including VEGFA, in ADIRF-AS1 KO cells that was only rescued by decitabine
treatment, and not by EZH2 or LSD inhibitors, we hypothesized that knocking out
PBRM1 prior to ADIRF-AS1 would rescue expression of PBAF target genes. We
used CRISPR-cas9 with flanking sgRNAs to knock out ADIRF-AS1 in 786O
control or PBRM1 KO cells (Fig 21a, b). After screening clones for an ADIRFAS1 single KO from the 786O sgCtrl population, we found only a single ADIRFAS1 KO clone, and this clonal cell line consistently demonstrated lower levels of
PBRM1, likely a stochastic clonal difference as there was no such change in the
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CRISPRi mediated ADIRF-AS1 KD 786O cells (Fig 15b) nor the ADIRF-AS1
single KO clones without an additional control sgRNA (Fig 16d). First, by RTqPCR of seven previously described PBAF suppressed genes66, ALDOC was
significantly induced by PBRM1 KO under normal culture conditions, suppressed
by ADIRF-AS1 KO, but not suppressed when ADIRF-AS1 was knocked out after
PBRM1 loss (Fig 21c).

Figure 21: 786O PBRM1 and ADIRF-AS1 DKO cells. A. Immunoblot analysis of
PBRM1 and αTubulin and B. RT-qPCR of ADIRF-AS1 in 786O control
(lentiCRISPRv2 sgCtrl and PX458 sgEV: CE) ADIRF-AS1 KO (CA), PBRM1 KO
(PE), and PBRM1 and ADIRF-AS1 KO (PA, clonal lines c5 and c47) C. RT-qPCR
analysis of ALDOC in control, single ADIRF-AS1 KO, PBRM1 KO, and DKO
cells. (RE > 3)

Next, we carried out Quant-seq analysis using three single KO clones as
well as the ADIRF-AS1 KO from the sgCtrl 786O cell population (referred to as
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“CA”) along with the DKO control cells (sgCtrl and sgPBRM1 with the PX458
sgEV, “CE” and “PE”) and two DKO clonal cell lines (sgADIRF-AS1/sgPBRM1,
“PA”) to determine genes that are differentially expressed by loss of ADIRF-AS1
in a PBRM1 dependent manner. First, using PCA we found that the PA DKO
cells clustered along with the PBRM1 KO cells and apart from the CE and CA
cell lines (Fig 22a). We found that PBRM1 dependent differentially expressed
genes in ADIRF-AS1 KO cells were predominantly associated with cell cycle (Fig
22b, c), similar to our finding that cell cycle genes lost rhythmic expression in
U2OS cells.
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Figure 22: 786O PBRM1 and ADIRF-AS1 DKO cells rescue cell cycle genes.
A. PCA plot of Quant-seq 3’ mRNA-sequencing for DKO cell lines. B. Heatmap
and C. gene ontology for biological processes of genes differentially expressed in
ADIRF-AS1 KO lines with rescued expression in the PA DKO cell lines (569
genes).

The DKO did not rescue decreased Hallmark Hypoxia by GSEA analysis,
but PE (PBRM1 KO) cells did not exhibit increased Hallmark Hypoxia under
normoxic, normal media conditions, highlighting the caveats of this in vitro
analysis, as many gene expression changes due to PBRM1 loss are in response
to in vivo stresses (Fig 23a). However, cell cycle genes, such as WEE1 and
BARD1 (Fig 23b) and specific genes associated with the hypoxia response that
were differentially expressed by loss of ADIRF-AS1 were rescued by DKO cells
(ALDOC, PDK1, GLUD1) (Fig 23c). This data strongly suggests that PBRM1 is
necessary for decreased expression of these genes upon ADIRF-AS1 loss,
which is consistent with our previous finding that decitabine treatment resulted in
increased expression of target genes.
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Figure 23: PBRM1 dependent gene expression changes. A. GSEA analysis
of Hallmark P53 Pathway and Hypoxia in 786O ADIRF-AS1 KO, PBRM1 KO,
and DKO cells. B. Normalized counts of WEE1 and BARD1 and C. ALDOC,
PDK1, and GLUD1.

Blunted tumorigenesis by ADIRF-AS1 loss is partially dependent on PBRM1
expression
Given that PBRM1/ADIRF-AS1 DKO cells had rescued expression of
many but not all DEGs, we hypothesized that PBRM1/ADIRF-AS1 DKO cells
would have partially rescued tumorigenesis. Surprisingly, we found that DKO
cells (PA) also lacked tumorigenesis and were not significantly different from the
single KO cells (CA) (Fig 24a, b). This finding demonstrates that ADIRF-AS1 has
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PBRM1 independent function. Transcriptomic analysis of the top 100
downregulated DEGs in ADIRF-AS1 KO and DKO cells showed loss of genes
associated with the ECM (Fig 24c), as we also found in ADIRF-AS1 KO U2OS
cells. Among these differentially expressed ECM genes, we found that decreased
expression of NID1 (also known as entactin), which makes up approximately 8%
of Matrigel100, was significantly downregulated in both the single KO and DKO
cells (Fig 24d). NID1 is a component of the ECM that binds laminin-1 and
collagen type IV and can also bind cell surface receptors such as integrins101 to
regulate ECM remodeling102. Thus, we hypothesized that both PBRM1
dependent and independent roles of ADIRF-AS1 on tumorigenesis could be
rescued only in DKO cells in the presence of Matrigel, to restore NID1 in the
ECM. Consistent with our hypothesis, we found that when co-injected with
Matrigel the ADIRF-AS1 single KO (CA) did not form tumors whereas the DKO
cells formed tumor xenografts, with some clonal variation. While the Pac5 DKO
cell line grew similarly to the CE control group and at day 35 had significantly
larger tumor weight compared to the single KO CA group, the Pac47 DKO cell
line formed tumors that began to shrink around day 29 and by day 35 were not
significantly larger than the CA cohort. However, we were able to collect residual
tumor tissue from the Pac47 group, unlike the CA cohort (Fig 24e, f). However,
the tumor volume (ANOVA p-value, PAc5= 0.0037 and Pac47= 0.0004) and
weight (ANOVA p-value, PAc5 <0.0001 and Pac47 <0.0001) of the DKO cell
lines were significantly decreased compared to single PBRM1 KO cells (PE),
which could be due to the transient nature of Matrigel. This striking phenotype
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demonstrates that ADIRF-AS1 is necessary for tumorigenesis in 786O ccRCC
cells in a PBRM1-dependent and unique ECM-dependent manner.
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Figure 24: PBRM1 loss partially rescues tumorigenesis of ADIRF-AS1 KO
786O cells in the presence of Matrigel. A. Tumor volume and B. weight of
DKO control, ADIRF-AS1 or PBRM1 single, and DKO 786O cells in the absence
of Matrigel. (ANOVA, combined two independent injections) C. The top 100 most
downregulated genes across all ADIRF-AS1 KO cell lines. D. Normalized counts
of NID1 in DKO cell lines. (ANOVA, RE of 2) E. Tumor volume and F. weight of
DKO control, ADIRF-AS1 or PBRM1 single, and DKO 786O cells in the presence
of Matrigel. (ANOVA, combined two independent injections)
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Chapter 3: Conclusions and Future Directions
Conclusions
We have shown that the molecular clock regulates the lncRNA ADIRFAS1 and that ADIRF-AS1 binds the PBAF complex to antagonize PBAF activity.
The molecular clock coordinates metabolism, and while independent of the cell
cycle, the molecular clock can couple with the cell cycle to separate energetically
opposed catabolic and anabolic processes10. Thus, the unique regulation of
ADIRF-AS1 by BMAL1 suggests that the timing of ADIRF-AS1 expression is an
important aspect of its function. Through loss of function studies and time course
transcriptomics analysis, we found that one function of ADIRF-AS1 is to bind to
and antagonize the PBAF complex. This suggests that ADIRF-AS1 may
antagonize the PBAF complex in a temporally regulated manner, adding an
accessory level of regulation to this important tumor suppressor complex. This
temporal regulation, which is evident from our finding that loss of ADIRF-AS1
resulted in disruption of cell cycle gene oscillations, may enable tissue and gene
specificity of PBAF chromatin binding.
Prior to our study, the PBAF complex has been shown to regulate clock
amplitude by re-organizing chromatin in mouse liver103. While in U2OS cells loss
of ADIRF-AS1 had no effect on central components of the molecular clock, cell
cycle genes lost high amplitude circadian oscillation. While loss of ADIRF-AS1
had no reproducible effect on protein levels of PBRM1 or other PBAF subunits, it
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may be that periodic ADIRF-AS1 binding to the PBAF complex suppresses PBAF
activity at specific loci at the peak of ADIRF-AS1 expression. While circadian
PBAF expression was observed in mouse liver103, a study of diurnal gene
expression in human tissues using the algorithm CYCLOPS (cyclic ordering by
periodic structure) did not find significant, oscillating mRNA expression of
SWI/SNF components across multiple human tissues84, but this does not
preclude oscillating complex activity. In a study of mouse liver, Koike et al
demonstrated that only 22% of the circadian transcriptome was directly regulated
by de novo transcription, and that RNAPII recruitment and chromatin remodeling
was the main driver of diurnal gene expression43. Nucleosome remodeling
complexes can regulate the circadian transcriptome by enabling pulsatile high
transcription, known as a transcriptional burst104, through multiple mechanisms
such as histone acetylation to regulate burst frequency105, and EZH2-mediated
histone methylation which is required for an intact molecular clock106. Thus, it
remains to be determined in human models if circadian gene expression requires
the PBAF complex, whose activity could be post-translationally regulated by
interaction with ADIRF-AS1 and/or other RNAs.
PBRM1 is mutated in many ccRCC cases, and there may be PBRM1 WT
tumors that exhibit low PBAF activity due to specific RNA mediated repression.
SWI/SNF complexes are phylogenetically conserved across biology, but through
combinatorial protein composition they regulate diverse sets of genes across
species and tissues107. RNA binding of SWI/SNF complexes allows for a rheostat
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for complex chromatin binding, having the potential to regulate the timing,
activity, and abundance of chromatin occupancy. While there have been multiple
studies demonstrating the RNA binding capacity of SWI/SNF complexes, few
RNA-protein interactions have been functionally characterized, as we do here for
ADIRF-AS1. SMARCB1 associated with specific RNAs in a proliferative
compared to a senescent state56. Understanding when and how functional
SWI/SNF-RNA interactions occur could allow for targeted modulation of these
extremely important complexes that are mutated in cancers53.
Just as a single mutated protein subunit can lead to vast changes in
SWI/SNF function, we show that gain or loss of ADIRF-AS1 lncRNA interactions
can also impact the PBAF complex function. While the PBAF complex is highly
phylogenetically conserved, ADIRF-AS1 is not. To date, there is no known
ADIRF-AS1 mouse orthologue, and ADIRF-AS1 expression is found
predominantly in primates. It is possible that this adds a species-specific layer of
regulation that is reflected in the differences of PBAF target genes in murine and
human ESCs107. In addition, in a study comparing hESCs and mESCs, even
conserved lncRNA have distinct species specific RNA processing and
localization108. The interaction between ADIRF-AS1 and the PBAF complex could
be an evolutionary gain of regulation of the PBAF complex that is hijacked in the
context of a cancer where PBAF is tumor suppressive.
We demonstrated that ADIRF-AS1 KO 786O cells exhibited decreased
expression of Vegfa that was rescued by a DNMT inhibitor but not EZH2
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inhibitors. In a study of chromatin dynamics, Iurlaro et al109 demonstrated that an
inhibitor of SWI/SNF ATPases lead to rapid changes in chromatin accessibility,
impacting gene expression. Washout of the inhibitor demonstrated widespread
reversibility of chromatin accessibility and gene expression109. In contrast to
histone modifications, the dynamics of DNA methylation are slower. In mESCs,
the transcriptional repressor REST depends on BRG1 for recruitment110. Thus, it
remains possible that this enables DNMT recruitment or activity at specific loci. In
this way, steady-state PBAF activity could be regulated by the circadian
expressed lncRNA, ADIRF-AS1, for maintenance of the circadian transcriptome
as we observed widespread dampening of clock-controlled cell cycle and not
core clock genes in ADIRF-AS1 KO U2OS cells.
PBRM1 mutation status and expression are used as therapeutic
biomarkers in multiple tumor contexts, including ccRCC, and thus our work
showing that ADIRF-AS1 antagonizes PBAF may have therapeutic implications.
We showed that ADIRF-AS1 is regulated by the molecular clock in PBRM1 WT
786O cells, temporally restricting the inhibitory function of ADIRF-AS1 on PBAF
activity. In PBRM1 WT ccRCC cases, there may be time of day therapeutic
windows associated with diurnal expression of angiogenic factors, possibly
regulated by cyclic ADIRF-AS1 modulation of PBAF activity. In addition, loss of
PBRM1 leads to elevated glucose uptake and lactate production71, increasing
media acidification, similar to hypoxia. Multiple hypoxia related pathologies, such
as obstructive sleep apnea, exhibit time-of-day variance and have been
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demonstrated to provoke misalignment of peripheral clock gene expression
patterns111. Our lab characterized the mechanism by which hypoxia mediated
acidification of media facilitates suppression of the circadian molecular clock via
lysosomal dispersion and mTOR suppression1. Thus, PBRM1 mutant tumors
may also suppress the molecular clock via acidification of the tumor
microenvironment.
We demonstrated that ADIRF-AS1 can negatively regulate the PBAF
complex, but ADIRF-AS1 likely has multiple functions. Using CRISPRi to
knockdown ADIRF-AS1 in 786O cells, we found that differentially expressed
genes were associated with angiogenesis and ECM, and U2OS ADIRF-AS1 KO
cells also had differentially expressed genes associated with ECM. We found that
ADIRF-AS1 KO 786O cells lacked the capacity to form tumor xenografts.
However, ADIRF-AS1 KO cells, when mixed with parental cells, persisted in
tumors, albeit the tumor sizes were blunted compared to controls. These findings
suggest that provision of factors by control cells were insufficient to fully rescue
the KO cells. Thus, it is possible that ADIRF-AS1 has additional PBRM1independent functions, such as regulating the expression of ECM genes.
Consistent with this notion, knocking out PBRM1 prior to ADIRF-AS1 CRISPR
mediated KO in 786O cells failed to rescue tumorigenesis in the absence of
Matrigel. In the presence of the ECM provided by Matrigel, the PBRM1/ ADIRFAS1 KO cells formed tumors while the ADIRF-AS1 KO remained non-tumorigenic
likely due to the unopposed tumor suppressive effect of PBRM1. Taken together,
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we found that ADIRF-AS1 is an important lncRNA that regulates tumorigenesis of
786O cells in part through antagonizing the PBAF complex.
Tumors harboring PBRM1 mutations are more susceptible to VEGF
inhibitors112 and PARP inhibitors75. Since tumors with high ADIRF-AS1
expression phenocopy PBRM1 null cells, they may be more responsive to antiangiogenic therapies and sensitive to PARP inhibitors. Similarly, PBRM1
expression is negatively correlated with immune checkpoint blockade (ICB)
response, and PBRM1 mutant tumors have an improved response to ICB
(NCT01984242). Thus, re-examination of the clinical responses in patients with
wild-type PBRM1 tumors with respect to high ADIRF-AS1 expression could
uncover an additional group of ccRCC patient that might benefit from ICB. Future
structural studies of the PBAF and ADIRF-AS1 complex could also yield new
therapeutic strategies that inhibit ADIRF-AS1 function and unleash the tumor
suppressive function of PBAF. In aggregate, our studies reveal that the circadian
lncRNA ADIRF-AS1 binds the PBAF complex and affects circadian expression of
cell cycle related genes and profoundly alters angiogenic gene expression and
786-O tumorigenesis in vivo.

Future Directions
ADIRF-AS1 function beyond ccRCC
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ADIRF-AS1 may play a role in tumorigenesis of other cancer types.
Despite components of the molecular clock having tumor suppressive function in
some cancer subtypes10,113, BMAL1 and CLOCK have recently been
acknowledged as having oncogenic functions in glioblastoma and low-grade
glioma114. In support of this discovery by Dong et al, we found that both high
BMAL1 and ADIRF-AS1 correlates with decreased survival in low grade glioma
(Fig 25a,b). Conversely, unlike in ccRCC as described in this body of work, high
ADIRF-AS1 expression correlates with improved survival in Head-Neck
Squamous Cell Carcinoma (HNSC) and Kidney Chromophobe (KICH) cancers
according to TCGA data (Fig 25 c, d), where PBRM1 is mutated in less than 3%
of both tumor types67. Thus, it is likely that the oncogenic function of ADIRF-AS1
is context dependent, similar to the cancer specificity of SWI/SNF mutations and
the molecular clock61. Of note, ADIRF does not correlate with survival in KICH,
HNSC, or LGG according to TCGA data (data not shown). In addition, the
genomic locus of ADIRF/ADIRF-AS1 is co-deleted along with PTEN in prostate
cancers, and copy number loss of ADIRF correlated with decreased survival115.
Thus, future studies could determine additional functions of ADIRF-AS1 in
pathophysiologic contexts other than ccRCC as well as during normal
physiology.
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Figure 25: ADIRF-AS1 expression correlates to survival in other cancer
types. Kaplan-meier plots of high versus low A. ADIRF-AS1 and B. BMAL1
expression in LGG (low grade glioma). Kaplan-meier plots of high versus low
ADIRF-AS1 expression in C. KICH (Kidney Chromophobe), and D. HNSC (HeadNeck Squamous Cell Carcinoma) TCGA cancer types.
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Mure et al analyzed time course transcriptomic data analysis of 64 tissues
collected every 2 hours for 24 hours from baboons, finding that over 80% of the
transcriptome exhibited diurnal expression in at least one tissue12. In this study,
ADIRF significantly oscillates in 6 tissues (Fig 26a), including multiple
components of the urinary tract. In addition, in an analysis of human data using
the algorithm CYCLOPs84, ADIRF exhibits a circadian profile in multiple human
tissues, including components of the vasculature system (Fig 26b). According to
the GTEx Portal, ADIRF-AS1 is highly expressed across multiple human tissues,
including the urinary tract and vasculature (Fig 26c). Circadian rhythms in blood
pressure and heart rate are disrupted in BMAL1 KO mice14,116 and the clock has
also been attributed to maintenance of vasculature stiffness117. While ADIRF is
not expressed at the protein level in U2OS and the ccRCC cell lines tested in this
study, ADIRF-AS1 could regulate ADIRF transcription as well as the PBAF
complex or ECM components during normal physiology in specific tissues.
Future studies could study the role of ADIRF-AS1 during normal physiology,
albeit complicated by the absence of an orthologue in rodents83. It would be
feasible to exogenously express ADIRF-AS1 in mice to determine if ADIRF-AS1
can antagonize specific functions of the PBAF complex or possible gain of
function on ECM component production.

78

Figure 26: ADIRF is circadian expressed in baboon and humans. A. The
significance (Metacycle p-value) of ADIRF circadian expression across 64
baboon tissues (BLA: bladder, PRC: prefrontal cortex, MUG: muscle
gastrocnemian, ASC: ascending colon, TES: testicles, ADM: adrenal medulla)12.
B. The calculated significance of ADIRF according to human CYCLOPs data84.
79

C. Tissue specific RNA expression of ADIRF-AS1 from the GTex Portal database
(https://platform.opentargets.org/target/ENSG00000272734 ).

Our findings indicate that ADIRF-AS1 has PBRM1-independent
tumorigenic functions. Although lncRNAs could modify the function of miRNAs,
our proteomics analysis of ADIRF-AS1 binding partners revealed that in addition
to PBAF components, ADIRF-AS1 also pulled down nucleolar proteins
GLTSCR2 and AATF (Fig 27a, b). GLTSCR2 has been previously found to
regulate p53 during ribosomal stress118, thus, one could hypothesize that ADIRFAS1 might play a role in retention of GLTSCR2 in the nucleolar region. Upon
ribosomal stress, such as hypoxia, BMAL1 protein is reduced leading to
decreased ADIRF-AS1 and release of GLTSCR2 into the nucleoplasm to
stabilize p53. While this remains to be determined, in our 786O DKO
transcriptomic analysis, the p53 response pathway was enriched in the ADIRFAS1 single KO (CA) and rescued in PBRM1/ADIRF-AS1 DKO (PA) cells (Fig
23a). Thus, the impact of ADIRF-AS1 loss on p53 target gene expression is likely
PBAF dependent. In addition, AATF is a transcription co-factor and has also
been shown to regulate the cell cycle and DNA damage response through
interacting with p53. However, unlike GLTSCR2 which does not correlate with
survival in ccRCC (data not shown), high expression of AATF in ccRCC
correlates with decreased survival only in PBRM1 WT and not PBRM1 mutant
tumors, similar to ADIRF-AS1 (Fig 27c, d). Further, AATF is a known RNA
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binding protein and via eCLIP-seq was shown to bind PBAF target genes,
VEGFA and ALDOC, in addition to ribosomal biogenesis RNAs119. Taken
together, ADIRF-AS1 could interaction with AATF could function to counter the
PBAF complex to promote HIF signaling in ccRCC. While the role of AATF in
ccRCC remains unexplored, it is possible that AATF functions to regulate the cell
cycle and DNA damage response in ccRCC only in the context of PBRM1 WT
tumors, and ADIRF-AS1 binds AATF to regulate its function. Thus, the
proteomics analysis conducted in our study contains multiple avenues for future
research on ADIRF-AS1 protein interactions, and it remains possible that ADIRFAS1 could also function independent of protein interactions to modulate miRNA
or DNA interactions.
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Figure 27: Alternative functions of ADIRF-AS1. A. The iBAQ proteomics
enrichment score for GLTSCR1 and B. AATF in ADIRF-AS1 compared to the
antisense negative control. C. Kaplan-Meier plots for AATF median expression in
PBRM1 WT and mutant ccRCC tumors (cBioPortal mutation status).

MYC regulation of ADIRF-AS1
Our lab has previously characterized the E-box binding transcription
factor, MYC, is able to outcompete BMAL1 to deregulate the molecular clock120.
As ADIRF-AS1 has an E-box binding site within its promoter region and is
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regulated by BMAL1, we hypothesized that ADIRF-AS1 may also be regulated by
MYC. Using the CCLE (Cancer Cell Line Encyclopedia) we found that ADIRFAS1 expression positively correlates with high MYC expression (p=0.041) (Fig
28a). Next, we sought to determine if diurnal ADIRF-AS1 expression would be
diminished after inducible over-expression of MYC in U2OS cells using the well
characterized MYC-ER system, which leads to a disrupted circadian
transcriptome through suppression of BMAL1 expression. We found that in the
MYC-on compared to MYC-off condition, ADIRF-AS1 expression no longer
oscillated, but maintained a higher expression, similar to NR1D1 (Fig 28b). In
contrast, loss of BMAL1 in U2OS cells reduced ADIRF-AS1 expression,
suggesting that MYC, while suppressing BMAL1 expression and disrupt ADIRFAS1 oscillation, could induce higher ADIRF-AS1 expression. In addition to U2OS
cells, we found a similar expression pattern in SKNAS human neuroblastoma
cells (Fig 28c) adding evidence that ADIRF-AS1 can be induced by MYC in
addition to BMAL1.
MYC has also been shown to regulate the SWI/SNF complex. For
example, apart from its role on chromatin accessibility, SMARCB1 can directly
bind to MYC to inhibit DNA binding121. Thus, we asked whether in the MYC-ER
system if increased MYC expression led to any transcriptional changes in
SWI/SNF components. We found that U2OS MYC-on cells showed that
SMARCA4 (BRG1) was upregulated and SMARCA2 (BRM) was downregulated
(Fig 28d), an important switch in SWI/SNF ATPase that can be associated with
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increased disease severity122. In small cell lung cancer (SCLC), SMARCA4
directly regulates the expression of MAX (MYC-associated factor X), and
decreased SMARCA4 is toxic in SCLC cells that harbor MAX mutations123.
ADIRF-AS1 expression positively correlates with MYC expression in SCLC (Fig
28e). Thus, it is possible that MYC induced ADIRF-AS1 plays a regulatory role
on the SWI/SNF complex in SCLC. Future work could determine how oncogenic
MYC leads to increased ADIRF-AS1 to further modulate the activity of the
SWI/SNF complex and additional functions of ADIRF-AS1 in tumorigenesis.
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Figure 28: MYC regulation of ADIRF-AS1 and the PBAF complex. A. ADIRFAS1 positively correlates with MYC across the CCLE (Cancer Cell Line
Encyclopedia). B. RT-qPCR analysis of ADIRF-AS1 expression in synchronized
MYC-ER expressing U2OS and C. SKNAS cells treated with vehicle control or
tamoxifen (4OHT) (MYC-on) where RNA was collected every 4 hours for 52
hours. D. Normalized counts of U2OS MYC-off and MYC-on across the timecourse. E. ADIRF-AS1 correlation with MYC in SCLC (study: Plamadeala - 410 fRMA - u133p2; collected from the R2 database).

Circadian rhythm in ccRCC
In order to determine whether ADIRF-AS1 is circadian regulated amongst
multiple ccRCC cell lines, we used both HIF-1α (H1) and HIF-2α (H2) expressing
ccRCC cell lines124. For each cell line, we stably expressed the ADIRF-AS1
luciferase reporter construct. In order to minimize the effect of media
acidification, cells were cultured in media buffered against acidification as
described in Walton et al1. We found that amongst these cell lines, the ADIRFAS1 luciferase reporter exhibited robust oscillation in 786O and A498, no
oscillation in RCC4 and 769P, and weak oscillation with possible disrupted
periodicity in UMRC2 and RCC10 cell lines (Fig 29a-c). The periodicity of the
ADIRF-AS1 reporter luciferase signal did not seem to reflect HIF or PBRM1
mutation status. Future studies could further explore regulation of the molecular
clock in ccRCC.
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Figure 29: ADIRF-AS1 oscillation in ccRCC cell lines. Continuous
luminescence monitoring of ADIRF-AS1::dLuc in A. 786O, A498, B. RCC4,
769P, C. UMRC2 and RCC10 ccRCC cell lines.

Other circadian lncRNA
Future studies could determine the function of other circadian lncRNA revealed
by our analysis (Table 1). From our list of circadian lncRNA, LINC01515 has
been shown to have an oncogenic function as a miRNA sponge in
nasopharyngeal carcinoma125. In addition, SNHG7 can also function as a miRNA
sponge and promote tumor progression in colorectal cancer126, and SNGH14 has
multiple known oncogenic modalities both as a miRNA sponge127 and though
interaction with FUS128. Thus, future studies could determine the role of clock
regulation on these lncRNA.

Matrigel
In the 1990s, the use of Matrigel co-injected with the cancer cell of interest in
mouse tumor xenografts gained for reducing noise in tumor formation. Matrigel is
a temperature sensitive protein mixture produced from a mouse sarcoma EHS
(Engelbreth-Holm-Swarm) cell line129,130. Matrigel is primarily composed of ECM
proteins laminin (~60%), collagen IV (~30%), entactin (~8%) and the heparin
sulfate proteoglycan perlecan (~2–3%)131. However, Matrigel also includes
growth factors, such as VEGF. Today, it is common practice to incorporate
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Matrigel, or a similar product, when utilizing a tumor xenograft model. In this body
of work, we found that loss of ADIRF-AS1 blocked tumorigenesis in 786O ccRCC
cells while PBRM1/ADIRF-AS1 DKO cells retain tumorigenicity only in the
presence of Matrigel. While we surmised that this is due to the depletion of NID1
(entactin), which makes up approximately 8% of Matrigel, in the ADIRF-AS1 and
in the DKO cells, it remains to be determined whether the growth factors or other
Matrigel components contribute to the rescued tumorigenesis. In addition, we
noted that Matrigel had an increased effect on PBRM1 KO cells compared to
control cells. It is possible that there is an increased dependency on the
presence of basement membrane components in the absence of PBRM1. This
relationship could be further interrogated in future studies.
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CHAPTER 4: Materials and Methods
Protein Immunoblotting
Following media aspiration, cells were washed once with cold PBS and then
harvested by scraping over ice with Mammalian Protein Extraction Reagent
(Thermo Fisher Scientific) supplemented with protease inhibitor cocktail
(Promega G6521), and two phosphatase inhibitors (Sigma P5726, P0044). After
collection of scraped cells and supernatant (or after suspending cells in lysis
buffer), lysis was allowed to continue on ice for at least 20 minutes. Protein
lysates were cleared by centrifugation at 13,000 rpm at 4° C and stored at -80
until further use. Lysate was thawed on ice, quantified with the DC Protein Assay
(Bio-Rad), and then equal ug of total protein were resolved by SDS-PAGE using
Criterion pre-cast Tris-Glycine 4-20% gradient gels (Bio-Rad). Protein was
transferred by dry transfer (iBlot) to nitrocellulose membranes, which were then
blocked in 5% BSA in TBST. Primary antibodies included BMAL1, REVERBα,
PBRM1, BRG1, PHF10, SMARCC1, SMARCB1, HIF-2α, anti-α-tubulin
(Calbiochem; 1:10,000).
Quantitative Real-Time PCR
RNA was collected (Qiagen, RNeasy) and reverse transcribed to complementary
DNA (cDNA) using the TaqMan Reverse Transcription Reagents (Invitrogen)
using the Oligo d(T) method. cDNA was then used as template for quantitative
real time PCR with specific human primers using Power SYBR Green PCR
90

master mixes (Thermo Fisher) using a ViiA 7 real-time PCR system (Applied
Biosystems). Target expression was normalized to B2M or 18S where indicated
and relative expression was calculated using the delta-delta CT method. For
qPCR timecourses, data is normalized to the respective 4-hour control time point.
Fractionation
Preparation of nuclear extracts
Nuclear extracts were collected as previously described66. In short, cells at
approximately 80% confluence were collected with a cell scraper and washed
with ice cold PBS twice, pelleted (1,000g for 3 min at 4 °C), resuspended in 5
pellet volumes of hypotonic buffer (10 mM Hepes, pH 7.5, 1.5 mM MgCl2, 10 mM
KCl, 1 mM EDTA, 1 mM EGTA, and 1 mM DTT) containing protease inhibitors
(Sigma) for 30 min, followed by disruption by passing through a 22G needle 10
times. The suspensions were then centrifuged at 1,000g for 10 min at 4 °C and
resuspended in 2.5 pellet volumes of the same hypotonic buffer, adjusted to 5M
NaCl to a final concentration of 420 mM, and rotated for 30 min at 4 °C. The
lysates were cleared, and the supernatants were collected.
Nuclear cytoplasmic fractionation RNA
RNA fractionation experiments were carried out according to manufacturer’s
protocol (ThermoFisher AM1921).
Cell synchronization
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Cell synchronization by dexamethasone was done by aspiration of media and
replacement with fresh media containing 0.1 uM dexamethasone (Sigma) at time
0132.
Luciferase reporter cell lines and monitoring
Generation of real-time luciferase reporters
U2OS cells stably expressing firefly luciferase under control of the mouse Arntl
promoter have been previously described1 where the luciferase has been
destabilized (“dLUC”) through addition of degradation sequences enabling it to
serve as a real-time reporter of the activity of the clock network133.
We also generated of U2OS, 786O, A498 and RCC4 cell lines that stably
express destabilized firefly luciferase (“dLUC”) under the control of the ADIRFAS1 promoter. We designed primers to PCR amplify the promoter of ADIRF-AS1
using publicly available cage data134,135. We then used Topo-TA cloning, and we
transferred the promoter region to pGL4.15(Promega) by restriction digest. The
pGL4.15[luc2P/Hygro] vector expresses the reporter gene luc2P(Photinus
pyralis) which contains an hPEST protein destabilization sequence, as described
above. Cell lines were generated by transfection (Lipofectamine 3000
Transfection Reagent, Life Technologies Inc.) followed by 100 ug/mL hygromycin
selection (Corning). The luciferase activity data shown in this paper exclusively
represents the luciferase activity of the firefly luciferase reporter using the
substrate for this enzyme (beetle luciferin, Promega).
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Real-time monitoring of luciferase reporters
Real-time luminometer (LumiCycle instruments, detailed below) continuously
measure bioluminescence from cultured cells, and the hardware requires a nonhumidified and “atmospheric” CO2 (i.e. non-elevated CO2) environment.
Therefore, previously described media used for these luminometers is DMEM
with buffering capacity appropriately adapted for atmospheric (0.04% CO2)
culture136 that is phenol-red-free DMEM [ 25 mM glucose, 4.2 mM (350 mg/L)
sodium bicarbonate (Gibco), 10 mM HEPES (Sigma), 5% FBS, and 1x penicillinstreptomycin (prepared by supplementation of USBiological D9812-05)]. Fresh 4
mM L-glutamine (Lonza) was added at the start of each experiment.
Reporter cells were plated in 24-well plates to be confluent at the start of
analyses. At time zero, culture plates were aspirated, administered fresh, phenol
red free media (glutamine free) supplemented 0.1 uM dexamethasone, 0.1 mM
beetle potassium luciferin (Promega) and glutamine (4mM), sealed against
desiccation with adhesive optical PCR plate film (24-well plates, Applied
Biosystems), and immediately placed in a Lumicycle-96 luminometer
(Actimetrics). Luminescence (counts/sec; “relative light units (RLU) per second”)
was recorded every 10 minutes for multiple days and exported to Excel
(Microsoft) with LumiCycle Analysis software (Actimetrics).
CRISPR-editing
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BMAL1 KO cell line
Bmal1 was silenced in U2OS Arntl::dLUC cells through CRISPR editing
previously described80.
ADIRF-AS1 KO cell lines
ADIRF-AS1 was silenced in U2OS Arntl::dLUC and parental 786O cells through
CRISPR editing using pSpCas9(BB)-2A-GFP (PX458) (a gift from Feng Zhang,
Addgene plasmid #48138). Paired sgRNA sequences designed using an online
CRISPR design tool (http://tools.genome-engineering.org) (set 1:
GCAAGGCATACACCGTACCGGGG, ATACACTCAGGGCTTGTTCCTGG; set 2:
CGGGTGGACGGGAACCGCTAGGG, TCAACCGTGCTCCTGCAGGGAGG).
Oligos were phosphorylated, annealed, and ligated into the PX458 backbone,
which was then transformed into bacteria, isolated, and verified by sequencing.
The empty PX458 vector was used as control. Approximately 1 million cells were
seeded in a 10 cm plates and the following day transiently transfected with 5 ug
of plasmid using Lipofectamine 3000 (Invitrogen) according to the manufacturer’s
directions. 24 hours later, GFP positive cells were sorted by FACS as single cells
into 96-well plates. Resulting clonal lines were then screened using flanking PCR
primers followed by gel electrophoresis. Subsequently, RNA was collected for
clones that were positive for a band indicating the loss of the gDNA locus for
ADIRF-AS1. Loss ADIRF-AS1 expression was determined by PCR amplification
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with primers specific to control or ADIRF-AS1 KO (as in Fig 5d) followed by RTqPCR.
786O DKO cell lines
For DKO cells, 786O sgCtrl and sgPBRM1-1 (lentiCRISPRv2) polyclonal cell
lines were transfected using PX458 with flanking sgRNAs targeted to ADIRF-AS1
(set 2: GCAAGGCATACACCGTACCGGGG,
TCAACCGTGCTCCTGCAGGGAGG) or the empty vector control, as described
above.
786O CRISPRi cell lines
Plasmid pMH0001 contains a catalytically dead Cas9 fused to BFP fused to a
KRAB repressive domain (dCas9:BFP:KRAB) generated by Jonathan Weissman.
Purchase at Addgene (https://www.addgene.org/85969/). Lipofectamine infection
of sub-confluent (50%) 293 T cells with pMH0001 DNA viral plasmids following
lentivirus protocol. Infect parental 786O cells at 25% confluence with pmH0001
virus and polybrene at 8µg/mL. (1:1200 dilution-For convenience: polybrene at
10 mg/mL stock use 8 µL for 10 mL media and 2.4µL for 3mL media). Replace
the media of the infected cells the morning after infection (polybrene is toxic) and
allow the cells to culture as normal for about 1 week.
Next, we flow sorted cells for BFP positive population as follows: 24 hours before
cell sorting, switch the media on the cells to phenol red-free medium. (The
phenol red in media will make sorting for BFP incredibly difficult!) On the day of
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cell sorting, harvest the cells with Accumax (A7089-100mL Sigma) to avoid
phenol red in trypsin and to prevent clumping and the forming of doublets. Wash
cells with 10 mL PBS, pellet, and remove as much supernatant as possible.
Repeat wash. Resuspend the cells in approximately 500 µL 2%FBS/PBS mixture
followed by BFP sorting through The Wistar Institute flow core. Cells were sorted
for BFP twice to ensure high expression of dCas9.
Next, I generated gene-specific sgRNAs for CRISPRi as previously described137.
The sgRNAs tested for ADIRF-AS1 were used from the following lncRNA library:
http://science.sciencemag.org/content/355/6320/eaah7111 as previously
described138. The protospacer sequences were used: #4
(CACCGGCGGGCACGCAGGCAACCCG) and #7
(CACCGGGGCCGCCTGAAGTCCTGAG) provided the best knockdown
efficiency as measured by RT-qPCR. We also used the NC and ROSA negative
controls in addition to the CDK1 and CDK9 positive controls. Oligos were ordered
from IDT and were resuspend the oligos from IDT at 100 µM in purified water.
Annealed oligos and clone into LRG2.1T vector backbone (lentivirus, GFP
expressing). Lipofectamine infection of sub-confluent (50%) 293 T cells with
sgRNA LRG2.1T DNA and viral plasmids was carried out as described. Infect
CRISPRi cells (as described above) with the sgRNA LRG2.1T virus. GFP sort
cells and assess knockdown by RT-qPCR analysis.
Timecourse design
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All 52-hour timecourses with 4-hour intervals of RNA and protein lysate harvest
were collected as two staggered 24- and 28-hour parallel timecourses. U2OS
Arntl::dLUC cells were seeded at near confluency in 10cm dishes and allowed to
grow in normal DMEM in 5% CO2. Twenty-four hours later, another set of plates
was similarly plated. After 24 hours, cells of the first set were treated with fresh
media and synchronized. Twenty-four hours later, the second set of plates was
also synchronized. Harvest of RNA or protein began at the indicated intervals
with the 4-hour and 28-hour samples being collected together, followed by the 8hour and 32-hour samples and so forth.
lncRNA pulldown followed by proteomics
In order to pull down proteins associated with ADIRF-AS1, we used a previously
reported protocol139. The full-length sequence of ADIRF-AS1 was retrieved from
U2OS cDNA using sequence specific primers (For:
CTTGGGATGAGAGGACTGGG, Rev: AGCATGCAAGGGGAAATCAG) using
Phusion High-Fidelity PCR Kit (ThermoFisher F553L) with the GC Buffer. The
cDNA sequence of ADIRF-AS1 was cloned into pBluescript II SK (+). Biotinlabeled RNAs were transcribed in vitro using a biotin labeling mix (Roche) and T7
polymerase (Roche) from linearized pBluescript II SK plasmid following the
manufacturer’s instructions. Biotinylated RNAs were purified and 3 μg of
biotinylated RNA in RNA structure buffer (10 mM Tris-HCL pH 7, 0.1 M KCl, 10
mM MgCl2). To allow proper secondary structure formation, RNA was heated to
95°C for 2 min, put on ice for 3 min, and left at room temperature (RT) for 30 min.
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Folded RNA and tRNA (0.1 µg/µl) were then mixed with U2OS whole cell lysate
(containing 200ug proteins) in 500 μl RIP buffer (150 mM KCl, 25 mM Tris-HCl
pH 7.4, 5 mM EDTA, 0.5 mM DTT, 0.5% NP40, 100 U/ml RNase Out, protease
inhibitor cocktail) and then incubated at RT for 1 hour. 50 μl washed Streptavidin
agarose beads (Invitrogen) were added to each binding reaction and further
incubated at RT for another 1 hour. Beads were washed briefly with B&W (10mM
Tris-HCl (pH 7.5), 1mM EDTA, 2M NaCl) three time and B&W+0.01% Tween-20
three times and boiled in SDS buffer. Then the retrieved proteins were analyzed
on SDS gels followed by silver staining. Aliquots were then submitted for mass
spectrometry analysis.
Proteins pulled down by ADIRF-AS1 and negative controls were submitted to the
Wistar Proteomics and Metabolomics Core Facility for LC-MS/MS analysis. In
brief, samples were run on a 12% Bis-Tris NuPage gel for 0.5 cm, stained with
Colloidal blue, and the entire stained region of each lane was digested with
trypsin. The digested peptides were analyzed by LC-MS/MS on a Q Exactive HF
mass spectrometer. MS/MS spectra generated from the LC-MS/MS runs were
searched using full tryptic specificity against the UniProt human database
(www.uniprot.org; 10/01/2017) using the MaxQuant 1.6.0.16 program. False
discovery rates for protein and peptide identifications were set at 1%. Protein
quantification was performed using unique+razor peptides. Razor peptides are
shared (non-unique) peptides assigned to the protein group containing the most
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unique peptides (Occam's razor principle). False discovery rates for protein and
peptide identifications were set at 1%.
RNA 3’ End desthiobiotinylation Pulldown
RNA pulldowns were performed using the Pierce RNA 3’ End desthiobiotinylation
kit (Thermo Scientific, 20163) per manufacturer’s instructions. In brief, T4 RNA
ligase was used to attach a biotinylated nucleotide to the 3’ terminus in vitro
transcribed RNA (MEGAscript T7 Transcription Kit, Invitrogen, catalog number:
AM1334), ADIRF-AS1 or the antisense control in pBluescript SKII+ (gift from Dr.
L Zhang). Labeled RNAs were subsequently used to carry out RNA pull-down
assays (Thermo Scientific Pierce Magnetic RNA Pull-Down Kit, Product No.
20164) using nuclear cell lysate per manufacturer’s instructions. In Brief, labeled
RNAs (50 pmol) were bound to streptavidin magnetic beads (50ul). Protein-RNA
binding buffer was used to incubate 200ug nuclear lysate with bead bound
labeled RNAs (786O or U2OS) at 4°C overnight. Next, the beads were washed
(x3) and eluted in 24ul followed by western blot analysis.
RNA Immunoprecipitation
The binding of PBRM1 protein with ADIRF-AS1 was verified in this study by the
RIP assay using the EZ-Magna RIP™ RIP Kit (Merck) following the
manufacturer’s instructions, in combination with qPCR method. Briefly, 786O and
U2OS nuclear lysate was collected as described above, incubated with magnetic
beads containing antibodies specifically recognizing PBRM1 (Cell Signaling,
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PBRM1/BAF180 (E9X2Z) Rabbit mAb #89123), and incubated with Proteinase K.
Magnetic beads conjugated with antibodies targeting human IgG were used as
the negative control. After washing steps (RIP wash buffer x5, RIP wash buffer +
2M Urea x1), RNA samples bound in magnetic beads were eluted and used as
the templates for RT (Invitrogen, SuperScript™ III First-Strand Synthesis
System). The relative contents of ADIRF-AS1 in elutes were analyzed by qPCR
method.
siRNA knockdown
Effective dicer-substrate short interfering RNAs (DsiRNAs, referred to as
“siRNA”) (IDT) were used for ADIRF-AS1 (#1:
ACTGAGAAAATGTTGGACAGAGGAA, #2:
GAACCAACCCAGTGGTCTCCTGACA) and Bmal1 knockdown (IDT TriFECTa
Kit DsiRNA ref No 279424187, verified knockdown using siRNA #2 and #3).
100,000 cells were seeded in 6-well dishes and allowed to expand in standard
DMEM in 5% CO2 incubators. The following day, cells were transfected with
DsiRNA at the concentrations indicated in the legends using Lipofectamine
RNAiMAX (Invitrogen) for 48 hours. Equimolar non-targeting DsiRNA was used
as a control.
Cell growth assays
The cell titer-glo luminescent cell viability assay was used per manufacturer’s
protocol to measure cell proliferation rates. In short, at day 0, 500 cells (100ul)
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were plated into 96-well opaque-walled dishes and baseline measured using cell
titer-glo. At each time point, media was aspirated and replaced with equal volume
fresh media (100ul). One volume (100ul) of room temperature CellTiter-Glo
Reagent was added to each well. Contents were mixed for 2 minutes on an
orbital shaker to induce cell lysis, and further incubated at room temperature for
10 minutes. Luminescence was measured by a microplate reader.
Xenografts
Renal carcinoma cells at 80% confluence were collected by trypsinization. After
centrifugation at 300 xg for 3 min at room temperature the cells were washed
twice with ice cold PBS and resuspended in ice cold PBS at a concentration of
1x10^7 or 1x10^7 cells/ml. Two or five million cells (cell number indicated in
legends, 200 µl per injection) were injected subcutaneously into 5-8 week-old
nude mice using a BDSyringe with Sub-Q Needle 1mL (26 gauge). Tumors were
measured twice a week with calibers. Tumors were collected 40 to 60 days later.
Glycerol Gradient
Nuclear lysates (previously described) were loaded onto glycerol gradients (1045%) were made using hypotonic buffer (10 mM Hepes, pH 7.5, 1.5 mM MgCl2,
10 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 420mM NaCl). Gradients
were centrifuged using Thermo AH-650 swinging bucket using 5ml ThermoFisher
PA thin-walled tube (cat. No. 03127) at 39,800 rpm for 18 hrs at 4°C.
3’RNA Quant-seq
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RNA isolation for sequencing
786O cells expressing dCas9-BFP-KRAB (Addgene #85969) and LRG2.1T
(sgRNA against NT, ROSA or ADIRF-AS1 and GFP) were seeded at 150,000
cells/ml. After 48 hours, total RNA was collected (Qiagen, RNeasy). For DKO
cells, 786O sgCtrl and sgPBRM1-1 (lentiCRISPRv2) polyclonal cell lines were
transfected using PX458 with flanking sgRNAs targeted to ADIRF-AS1 (set 2:
GCAAGGCATACACCGTACCGGGG, TCAACCGTGCTCCTGCAGGGAGG) or
the empty vector control. Single cell clones were screened as described above
using primers flanking the cut site. DKO cell lines were seeded at 150,000
cells/ml into 6 well plates and total RNA was collected after 48 hours (Qiagen,
RNeasy).
Sequencing Preprocessing
Sequencing libraries were prepared using the Lexogen‘s QuantSeqTM 3‘ mRNASeq Kit for Illumina per manufacturer’s instructions by the Wistar Genomics core.
RSEM along with Bowtie2 was used for alignment. All reads within any
transcript’s coding part of a gene were counted to get expression for each gene.
DESeq2
Differential expression analysis was performed using raw count values with the
DESeq2 R package through RStudio. First, the following cutoffs were used:
o 786O CRISPRi: triplicate, median raw counts over 5 for all
samples. This resulted in 15,289 genes total.
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o 786O single KO and DKO cell lines: triplicate, genes with raw reads
greater than 30% of values had raw counts over 5. This resulted in
15,663 genes total.
o U2OS timecourse: single RNA sample per timepoint, filtered out
genes to only include genes with counts greater than 5 in over 30%
of time points. This resulted in 16,015 genes total.
DESeq2 was then implemented by the following:
library("DESeq2")
dds <- DESeqDataSetFromMatrix(countData = cts,
colData = coldata,
design = ~ sgRNA)
dds <- DESeq(dds)
resultsNames(dds) # lists the coefficients
res <- results(dds, contrast=c("Treat","CAc17","CE")) # Example of
comparison

# Plot PCA plot
library(ggplot2)
rld <- rlog(dds)
plotPCA(rld, intgroup="Treat")
data <- plotPCA(rld, intgroup="Treat", returnData=T)
percentVar <- round(100 * attr(data, "percentVar"))
DKO <- ggplot(data, aes(PC1, PC2, color=Treat)) +
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geom_point(size=3) +
xlab(paste0("PC1: ",percentVar[1],"% variance")) +
ylab(paste0("PC2: ",percentVar[2],"% variance")) +
coord_fixed()+
theme_bw()

Heatmaps were generated using normalized counts either by ggplot2 or by
MORPHEUS (https://software.broadinstitute.org/morpheus/ ).
GSEA
Gene set enrichment analyses were performed using the Broad Institute GSEA
computational tool (https://www.gsea-msigdb.org/ ). Preprocessed normalized
counts were used. I used the online tool for GSEA run through the Amazon
Cloud service (https://www.genepattern.org/ ). The Hallmarks genesets were
used (h.all.v7.4.symbols.gmt) for Hallmark Hypoxia, Angiogenesis, and P53
Signaling.
Metacycle
For time-course data, circadian expression analysis (including amplitude, period)
was performed using the Metacycle R package through RStudio. Implementation
was according to the following:
# Packages used for data processing and heatmaps:
library(devtools)
library(MetaCycle)
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library(reshape)
library(reshape2)
library(dplyr)
library(cowplot)
# Run Metacycle on each input file
for(dir in list.files()){
cyc <- meta2d(infile=dir, filestyle="csv",
outdir="output", timepoints=seq(4, 52, by=4),
cycMethod=c("JTK","ARS", "LS"), outIntegration="both")}

Gene Ontology
Gene ontology analysis was performed through the ToppGene Suite via
ToppFun (https://toppgene.cchmc.org/ ) or by ClusterProfiler4.0 as implanted by
the following:
BiocManager::install("clusterProfiler")
if (!requireNamespace("BiocManager", quietly = TRUE))
install.packages("BiocManager")
BiocManager::install("org.Hs.eg.db")
# Input processing: Change Ensembl ID to Entrez for Cluster Profiler
genes.entrez <- bitr(up.genes$ENSG, 'ENSEMBL', 'ENTREZID',
'org.Hs.eg.db')
# Gene input from dataframe with 1st column Entrez ID and 2nd foldchange
## feature 1: numeric vector
geneList = genes.entrez[,2]
## feature 2: named vector
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names(geneList) = as.character(genes.entrez[,1])
## feature 3: decreasing orde
geneList = sort(geneList, decreasing = TRUE)

# The clusterProfiler package provides the enrichGO and
# gseGO functions for ORA and GSEA using GO
library(clusterProfiler)
# contains fold change of gene expression levels
#data(geneList, package="DOSE")
#attributes(geneList)
## fold change > 0 as DE genes
de <- names(geneList)[abs(geneList) > 0]
# retrieve GO terms:
library(org.Hs.eg.db)
ego <- enrichGO(de, 'org.Hs.eg.db', ont="BP", readable=TRUE)
ego2 <- simplify(ego, cutoff=.7, by="p.adjust", select_fun=min)
ego3 <- mutate(ego, richFactor = Count / as.numeric(sub("/\\d+", "",
BgRatio)))
# DEG Plot
library(ggplot2)
DEGsTot <- ggplot(ego3, showCategory = 10,
aes(-log(p.adjust, 10), fct_reorder(Description, log(p.adjust)),
fill = -log(qvalue,10))) +
geom_segment(aes(xend=0, yend = Description)) +
geom_bar(stat="identity")+
scale_fill_gradientn(colours=c("#7e62a3", "#46bac2", "#f7ca64"),
guide=guide_colorbar(reverse=F, order=1)) +
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scale_size_continuous(range=c(2, 10)) +
theme_dose(12) +
xlab("-log(p-adj)") +
ylab(NULL) +
ggtitle("Biological Processes")

TCGA Survival Analysis
Read mapping for ADIRF-AS1 in TCGA data was carried out as previously
described140. TCGA data for ccRCC (KIRC) was used, and cBioPortal
(https://www.cbioportal.org/ ) PBRM1 mutation status was used.
# Full code in:
setwd("Z:/Rebekah/RNA-seq Data/ADIRF-AS1/")
# saved as: 2018-3-16 ADIRF-AS1 KM using cBioportal ccRCC PBRM1
mut status
# In brief, analysis implemented as follows:
# Packages used:
library(survival)
library(plyr)
library(ggplot2)
library(scales)
library(GGally)
library(gridExtra)
library(devtools)
library(survminer)
library(gdata)
library(Hmisc)
library(reshape)
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library(reshape2)
# create survival object, example:
tissue.m$SurvObj <- with(tissue.m, Surv(Days.to.death.followup,
Status..1.death.0.survival. == 1))
# median cutoff was used; fit example:
km.as.one <- survfit(SurvObj ~ splice.sum.calc.HL, data = tissue.lh,
conf.type = "log-log")
# plot data, example:
plot <- ggsurvplot(km.as.one, main = "KIRC", pval = T, conf.int = T,
legend.labs = c("Low", "High"))
print(plot)
Other Kaplan-Meier analysis was carried out using the R2: Genomics Analysis
and Visualization Platform (https://r2.amc.nl/ ).

ChIP-qPCR
The SimpleChIP® Enzymatic Chromatin IP Kit (Magnetic Beads) (Cell Signaling,
#9003) was used for all chromatin immunoprecipitation (ChIP) assays. In brief,
786O cells were crosslinked using 1% formaldehyde followed by glycine. Cells
were washed with ice-cold PBS (x2), scraped and collected by centrifugation.
Prepared nuclei were used MNase mediated chromatin digestion after
optimization. For optimization, increasing concentrations of MNase were used
followed by RNAse A and Proteinase K digestion and DNA isolation. For ChIP
assays, 10ug chromatin was used. Diluted chromatin was combined with 10ul of
an antibody against Normal Rabbit IgG (1ul, Cell Signaling, #2729), H3K27ac
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(Acetyl-Histone H3 (Lys27) (D5E4) XP® Rabbit mAb #8173) or PBRM1 (Cell
Signaling, PBRM1/BAF180 (E9X2Z) Rabbit mAb #89123) overnight.
Resuspended ChIP-Grade Protein G Magnetic Beads (CS, #9006) were added
and incubated for 2hours at 4°C. Beads were washed with a low salt (x3) and
high salt (x1) washing buffer. Chromatin was eluted in elution buffer for 30mins at
65°C and cross-linking was reversed via proteinase K (overnight at 65°C). DNA
was subsequently collected per manufacturer’s instructions.
ChIP-seq
Samples were collected as described above. For next-generation sequencing,
ChIP-seq libraries were prepared from 10 ng of ChIP and input DNAs with the
NEBNext Ultra II DNA library Prep Kit for Illumina.

Data Processing
CHIP-seq data was aligned using bowtie141 against hg19 version of the human
genome and HOMER142 was used to generate bigwig files and call significant
peaks versus input and between pairs of samples using –style histone option.
Peaks that passed FDR<5% threshold were considered. Normalized signals for
significant peaks were derived from bigwig files using bigWigAverageOverBed
tool from UCSC toolbox143 with mean 0 option. Raw read counts for each peak
were obtained using HOMER using annotatePeaks.pls -raw option and
significance of differences between groups of samples was estimated using
DESeq2 algorithm144.
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Table 2: Reagents and resources
Reagent or Resource

Source

Identifier

Calbiochem

Cat#:CP06; RRID:AB_212802

Proteintech

Cat#:20359-1-AP;

Antibodies
Mouse monoclonal anti-α-tubulin
(clone DM1A)
Rabbit polyclonal anti-PER2

RRID:AB_10733224
Rabbit monoclonal anti-BMAL1 (clone

Cell Signaling

Cat#:14020; RRID:AB_2728705

Cell Signaling

Cat#:5157; RRID:AB_10695411

Rabbit polyclonal anti-CRY2

Epitomics

Cat#:T1225; RRID:AB_10706277

Mouse monoclonal anti-PBRM1

Cell Signaling

Cat#:81832

Cell Signaling

Cat#: 89123

Cell Signaling

Cat#: 13418

Rabbit polyclonal anti-Cyclin B1

Cell Signaling

Cat#: 4138

Rabbit monoclonal anti-p21 (12D1)

Cell Signaling

Cat#: 2947

Rabbit polyclonal anti-ADIRF

Atlas

HPA026810

Rabbit monoclonal anti-BRG1

Cell Signaling

Cat#: 49360

Rabbit polyclonal anti-PHF10

Abcam

ab154637

Rabbit monoclonal anti-SMARCC1

Cell Signaling

Cat #: 11956

D2L7G)
Rabbit monoclonal anti-CLOCK (clone
D45B10)

(clone E6N2K)
Rabbit monoclonal anti-PBRM1
(E9X2Z)
Rabbit monoclonal anti-Rev-Erba
(E1Y6D)

(D1Q7F)

(D7F8S)
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Rabbit monoclonal SMARCB1 (D9C2)

Cell Signaling

Cat #: 8745

Mouse monoclonal anti-DPF2 (C-9)

Santa Cruz

sc-514297

Rabbit monoclonal anti-HIF-2a

Cell Signaling

Cat#: 7096

eBiosciences

17-5071-42

Beetle luciferin, potassium salt

Promega

E1602;

Dexamethasone

Sigma D4902;

CAS 50-02-2

Dulbecco's MEM (DMEM) high

Corning

MT10-013-CV

RPMI-1640

Corning

10-040

Fetal bovine serum

HyClone,

SH30910.03

(D9E3)
BrdU Monoclonal Antibody (BU20A),
APC

Chemicals

glucose

Gemini
Bioproducts
High-vacuum silicone grease

Dow

Z273554

Corning/Sigma
G418 sulfate

Corning

MT30-234-CR

Hygromycin B solution

Corning

30-240-CR

Puromycin dihydrochloride

Gibco

A1113803

TaqMan Reverse transcription kit

Invitrogen

N8080234

iScript reverse transcription supermix

Bio-Rad

1708841

Mammalian protein extraction reagent

Thermo

PI78501

(M-PER)

Scientific
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Lipofectamine 3000 transfection

Invitrogen

L3000008

Invitrogen

13778150

NaCl, 5M solution

Invitrogen

AM9759; CAS 7647-14- 5

Bd 7AAD Staining Solution

BD

559925

RNeasy plus mini kit

Qiagen

74134

DC protein assay kit II

Bio-Rad

5000112

Power SYBR™ Green PCR Master

Thermo Fisher

436870

Millipore Sigma

17-700

Cell Signaling

9003S

Pierce™ Magnetic RNA-Protein Pull-

Thermo Fisher

20164

Down Kit

Scientific

MEGAscript™ T7 Transcription Kit

Invitrogen

AM1334

Tumor Dissociation Kit, human

Miltenyi Biotec

130-095-929

Phusion High-Fidelity PCR Master

Thermo Fisher

F531L

Mix with HF Buffer

Scientific

pCR 2.1-TOPO TA

Thermo Fisher

reagent
Lipofectamine RNAiMAX transfection
reagent

Critical Commercial Assays

Mix
Magna RIP™ RNA-Binding Protein
Immunoprecipitation Kit
SimpleChIP(R) Enzymatic Chromatin
IP Kit (Magnetic Beads)

451641

Scientific

Experimental Models: Cell Lines
Human: U2OS

Laboratory of Roger Greenberg ATCC HTB-96
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Human: U2OS Arntl::dLUC

Laboratory of John Hogenesch

Human: U2OS PX458 sgSCR

This study

Human: U2OS PX458 sgADIRF-AS1

This study

clone 1
Human: U2OS PX458 sgADIRF-AS1

This study

clone 2
Human: U2OS PX458 sgSCR GFP

This study

Human: U2OS PX458 sgADIRF-AS1

This study

clone 1 GFP
Human: U2OS PX458 sgADIRF-AS1

This study

clone 2 GFP
Human: U2OS sgSCR

This study

Human: U2OS sgBMAL1

This study

Human: U2OS ADIRF-AS1::dLUC

This study

Human: 786O

Laboratory of Celeste Simon

Human: 769P

Laboratory of Celeste Simon

Human: UMRC2

Laboratory of Celeste Simon

Human: A498

Laboratory of Celeste Simon

Human: CAKI2

Laboratory of Celeste Simon

Human: RCC4

Laboratory of Celeste Simon

Human: RCC10

Laboratory of Celeste Simon

Human: 786O PX458 sgSCR

This study

Human: 786O PX458 sgADIRF-AS1

This study

clone 23
Human: 786O PX458 sgADIRF-AS1

This study

clone 36
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Human: 786O PX458 sgADIRF-AS1

This study

clone 41
Human: 786O lentiCRISPRv2 sgCtrl

Laboratory of William Kaelin

Human: 786O lentiCRISPRv2

Laboratory of William Kaelin

sgPBRM1 sgRNA-1
Human: 786O lentiCRISPRv2

Laboratory of William Kaelin

sgPBRM1 sgRNA-2
Human: 786O dCas9-BFP-KRAB

This study

sgNT
Human: 786O dCas9-BFP-KRAB

This study

sgADIRF-AS1 sgRNA-4
Human: 786O dCas9-BFP-KRAB

This study

sgADIRF-AS1 sgRNA-7
Human: 786O lentiCRISPRv2 sgCtrl +

This study

PX458 sgEV ("empty vector")
Human: 786O lentiCRISPRv2 sgCtrl +

This study

PX458 sgADIRF-AS1 set2 c17
Human: 786O lentiCRISPRv2

This study

sgPBRM1 sgRNA-1 + PX458 sgEV
("empty vector")
Human: 786O lentiCRISPRv2

This study

sgPBRM1 sgRNA-1 + PX458
sgADIRF-AS1 set2 c17
Human: 786O ADIRF-AS1::dLUC

This study

Experimental Models: Cell Lines
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athymic nude mouse (Crl:NU(NCr)-

Charles River

Foxn1nu) - 490 (Homozygous)

Oligonucleotides
For qPCR primers, see Appendix
Table 2
For DsiRNA oligos, See Appendix
Table 2
sgRNA targeting ADIRF-AS1 (set 1):
GCAAGGCATACACCGTACCGGGG
sgRNA targeting ADIRF-AS1 (set 1):
ATACACTCAGGGCTTGTTCCTGG
sgRNA targeting ADIRF-AS1 (set 2):
CGGGTGGACGGGAACCGCTAGGG
sgRNA targeting ADIRF-AS1 (set 2):
TCAACCGTGCTCCTGCAGGGAGG
ADIRFAS1 Ci F4:
CACCGGCGGGCACGCAGGCAACC
CG
ADIRFAS1 Ci F7:
CACCGGGGCCGCCTGAAGTCCTG
AG

Recombinant DNA
pGL4.15[luc2P/Hygro] Vector

Promega

# 9PIE670

pSpCas9(BB)-2A-GFP (PX458)

Laboratory of

Addgene plasmid #48138

Feng Zhang
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psPAX2

Laboratory of

Addgene plasmid #12260

Didier Trono
pMD2.G

Laboratory of

Addgene plasmid #12259

Didier Trono
pBluescript SK (+)

Laboratory of
Lin Zhang

Software and Algorithms
LumiCycle Analysis software, v. 2.56

ActiMetrics

http://actimetrics.com/products/lumi
cycle/

Rstudio, v. 1.2.5019

Rstudio

https://www.rstudio.com/

MetaCycle (includes ARSER), v. 1.2.0

Wu et al., 2016.

https://cran.rproject.org/web/packa
ges/MetaCycle/index.html

ToppFun, version accessed

Chen et al.,

https://toppgene.cchmc.org/enrich

8/11/2021

2009.

ment.jsp

ggplot2

Hadley
Wickham

FlowJo

FlowJo

Prism, v. 8.4.3

Graphpad
Prism

Excel, 2016
survival, v 3.1-8

Terry M

https://github.com/therneau/survival

Therneau
survminer v 0.4.6

http://www.sthda.com/english/rpkgs
/survminer/

116

DESeq2, v 1.26.0

Michael Love

https://github.com/mikelove/DESeq
2

R2: Genomics Analysis and

https://hgserver1.amc.nl/cgi-

Visualization Platform

bin/r2/main.cgi

UCSC Genome Browser

http://genome.ucsc.edu/

GSEA (Gene Set Enrichment

UC San Diego

Analysis)

and Broad

https://www.gsea-msigdb.org/gsea

Institute

Table 3: qPCR Primers
q

Target
ADIRF-AS1
VEGFA
REVERBa
ANGPTL4
IGFBP3
CCND1
SLC2A1
PDK
ALDOC
PBRM1
NID1
PXDN

Sequence (Forward)
TGCCTTACCCAGATCCCAT
GCG CTG ATA GAC ATC CAT GA
TGGACTCCAACAACAACACAG
CCACCGACCTCCCGTTA
CAGCATGCAGAGCAAGTAGA
AGCACTTTCAGTCCAATAGGTGT
GTG CCA TAC TCA TGA CCA TCG
CAAGAAGCTCCTGAAGACTCTG
CCTCATCTGTTTGCGGATCA
CAAGTCAATGGGCTGAGAAAC
ATACCATGAGGAAGACAGAAGC
AGGTTCAGGTACTGTGGAGA
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Sequence (Reverse)
CCCACAGTTCTTCCCTTGAG
CCA TGA ACT TTC TGC TGT CTT G
GATGGTGGGAAGTAGGTGGG
TTGTGGAAGAGTTGCTGGAT
GTCATGTCCTTGGCAGTCTT
ACTTGCCTCAAAGTCCTGCTT
GGC CAC AAA GCC AAA GAT
CAAGAGTTGCCTGTCAGACTG
GACAACTCCTTCTTCTGCTCA
CTATAAGGATGAACAGGGCAGAC
CCATGTAGACTAGCTCTCCCA
ACATTGCAGCTCATTCAGGAG
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